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Det har vært en økende interesse for vitamin D sin rolle i patogenese av 
inflammasjonsrelaterte sykdommer, metabolske forstyrrelser, hjertekarsykdommer og cancer. 
Mange observasjonsstudier har antydet en sammenheng mellom redusert vitamin D nivå og 
økt risiko for disse sykdommene. Vårt mål var å undersøke denne sammenhengen i to store 
observasjonsstudier: den norske Tromsøundersøkelsen og den amerikanske NHANES 
(National Health and Nutrition Examination Survey), samt at vi har gjennomført to 
randomiserte studier (RCTer) for å vurdere om vitamin D tilskudd kan virke positivt på 
inflammasjonsmarkører. I Tromsøundersøkelsen (Tromsø 6) fant vi at redusert nivå av serum 
25-hydroxyvitamin D (25(OH)D) var assosiert med høyere verdier av high-sensitive CRP (hs-
CRP). Dessverre kunne vi ikke bekrefte kausal sammenheng i en RCT som gikk over 5 år, 
hvor vi testet om høy dose vitamin D (20 000 IU cholecalciferol per uke) kunne redusere 
serum hs-CRP. I en annen RCT hvor vi inkluderte overvektige personer, ble deltagerne delt i 
tre grupper og ble randomisert til enten høy dose cholecalciferol (40 000 IU per uke), 
cholecalciferol i dose 20 000 IU per uke eller placebo; og deretter fulgt i ett år. Vi fant at 
interleukin 6 verdiene falt, men tumor necrosis factor α og hs-CRP ikke ble redusert. Vi fant 
heller ingen effekt på insulinresistens. 
Data fra NHANES ble brukt for å studere assosiasjon mellom serum 25(OH)D og leukocyte 
telomere lengde (LTL). Forkortningen av telomere lengden er assosiert med genetisk 
predisposisjon for carcinogenese og tidlig aldring. Vi inkluderte 4260 menn og kvinner i ulike 
aldersgrupper og fant en positiv og selvstendig assosiasjon mellom serum 25(OH)D og LTL 
hos personer i aldersgruppen 40-59 år. Dette funnet støtter hypotesen om at redusert vitamin 
D status kan være assosiert med forøket risiko for kreft og andre aldersrelaterte sykdommer. 
Avslutningsvis, våre data indikerer at det er en assosiasjon mellom reduserte verdier av serum 
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There are several observational studies, suggesting an association between decreased vitamin 
D status and increased risk of cardiovascular diseases, metabolic and autoimmune diseases, 
and certain types of cancer. The relation between serum 25-hydroxyvitamin D (25(OH)D) and 
proinflammatory cytokines and some markers of carcinogenesis is still unknown and it is yet 
not established if supplementation with cholecalciferol reduces these markers. We used data 
from Tromsø study and from the U.S. National Health and Nutrition Examination Survey 
(NHANES) to study the association between 25(OH)D and proinflammatory cytokines and 
leukocyte telomere length (a marker of carcinogenesis and aging).  
In the observational study based on 10.118 non-smokers from the sixth Tromsø study we 
found a significant negative association between serum 25(OH)D and high-sensitive CRP (hs-
CRP). However, in a smaller cohort of subjects with prediabetes (n=511), there were no 
significant correlations between serum 25(OH)D and hs-CRP. Moreover, 5 years 
supplementation with 20 000 IU cholecalciferol per week did not result in significant 
reduction in serum hs-CRP levels, as compared with subjects receiving placebo. In another 
RCT, 1 year supplementation with 20 000 IU or 40 000 IU cholecalciferol, resulted in 
lowering of interleukin 6 (IL-6), but not hs-CRP and tumor necrosis factor-α. In another large 
observational study, based on NHANES cycles 2001-2002, we demonstrated the significant 
positive association between serum 25(OH)D and LTL, but only in middle-aged adults (e.g. 
age 40-59 years). The findings were independent of other risk factors for LTL shortening (e.g. 
age, race/ethnicity, BMI, intake of sugars and calories, physical activity, etc). These findings 
might provide the biological plausibility on vitamin Ds action on carcinogenesis and other 
ager-related conditions.  
In conclusion, the results of our study indicate an association between serum 25(OH)D levels 





supplementation with cholecalciferol for as long as 5 years, did not show a beneficial effect of 
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The rates of metabolic diseases, such as obesity and type 2 diabetes mellitus (T2DM), 
cardiovascular diseases (CVD) and cancer have reached pandemic levels and these diseases 
are on the top of leading causes of mortality worldwide [1]. That’s why it is not surprising, 
that in the past decades, we have seen increased scientific interest in the study of the 
pathogenesis of metabolic diseases, inflammatory conditions, cancer, aging processes and  
possible ways to prevent them. 
Vitamin D insufficiency is one of several factors that have been recently linked to these 
conditions, even though the main primary role of vitamin D has always been to maintain the 
healthy bone metabolism, and vitamin D insufficiency and deficiency was only mentioned in 
prevention of rickets and osteomalacia. 
Vitamin D deficiency has been associated with increased risks of systemic connective tissue 
diseases like rheumathoid arthritis, systemic lupus erythematosus [2], inflammatory bowel 
diseases, such as Crohns disease [3] and ulcerative colitis [4] and some malignancies [5]. 
Similar associations apparently also exist for infections [6], mortality in critically ill patients 
[7] and all-cause mortality [8, 9]. 
The findings in these observational studies are, of course, not proof of causality. Large 
randomized-controlled trials (RCTs) with metabolic and/or inflammatory diseases and 
malignancies as primary outcomes are needed to find out if the correction of vitamin D status 
is beneficial in the prevention of these diseases, and if the decreased levels of serum 25-
hydroxyvitamin D (25(OH)D) have a causal role in the pathogenesis of these diseases and 
conditions. Is the association between serum 25(OH)D and these diseases solely mediated by 





there some vitamin D mediated genomic changes involved? Will vitamin D supplementation 
(and in that case with which target level of serum 25(OH)D and for how long a time period) 
prevent occurrence and progression of metabolic diseases, inflammatory conditions and 
malignancies? These questions are yet to be answered, and the present thesis is hopefully a 
humble step towards some conclusions.  
We used two large population-based surveys: the Tromsø Study and the U.S. National Health 
and Nutrition Examination Survey (NHANES) to study if there are associations between 
serum 25(OH)D levels and markers of inflammation (such as, interleukin 6 (IL-6) and high-
sensitive C–reactive protein (hs-CRP)) and some markers of cancer (leukocyte telomere 
length (LTL)). Results from these observational studies generate many important hypotheses, 
but cannot be used as a final evidence for causal relationship between serum 25(OH)D and 
inflammation and cancer. We have therefore also performed two RCTs in order to find out if 
the supplementation with cholecalciferol (vitamin D3) affects the levels of these important 
biomarkers.  
1.1 Vitamin D 
Vitamin D is a fat soluble vitamin that exists in two forms; ergocalciferol (vitamin D2) and 
cholecalciferol (vitamin D3) that differ from each other with one double-binding and one 
methyl group [10, 11]. Vitamin D is mostly produced endogenously in the skin or obtained 
through the diet from fatty fish like salmon, mackerel, tuna, cod liver oil and vitamin D 
supplementation [5].  
Upon solar ultraviolet B exposure, 7-hydrocholesterol in the skin is converted to previtamin 
D3 [12]. Previtamin D3 undergoes heat-induced membrane-isomerization to vitamin D3 [13]. 
Vitamin D3 produced in the skin, along with vitamin D2 and D3 obtained through the diet are 





hydroxylation process occurs with the help of 25-hydroxylase (CYP2R1); and 25(OH)D, the 
major measured vitamin D metabolite, is synthetized [5]. 25-hydroxyvitamin D is an inactive 
metabolite and it undergoes further hydroxylation by 1 alfa-hydroxylase to turn into the 
biologically active metabolite 1,25 dihydroxyvitamin D (1,25(OH)2D) [14]. The 1 alfa- 
hydroxylase activity in the kidneys is auto-regulated by parathyroid hormone (PTH), which is 
in turn regulated through a negative feedback mechanism in the parathyroid glands depending 
on the calcium and phosphate levels in the serum. The main function of 1,25(OH)2D is 
maintaining the calcium and phosphorus homeostasis and accordingly promoting the bone 
health. 1,25(OH)2D stimulates increased calcium absorption in the gut, reduced excretion of 
calcium in the kidneys and increased calcium desorption from bone, which result in increased 
serum calcium. High serum calcium levels lead to stimulated production of fibroblast growth 
factor 23 from the bone cells, which in its feedback down-regulates 1 alfa-hydroxylase 
activity and thereby reducing secretion of 1,25(OH)2D and depleting serum calcium levels 
[15]. Regarding the choice of intervention time in our present and future RCTs it is worth 
mentioning that the half-life of 25(OH) D is two-three weeks and 1,25(OH)2D is 2-4 hours 
[15]. However, it is still not completely understood how and where 25(OH)D is stored [13]. 
Since half-life time for 25(OH)D is much longer, the serum concentrations of this inactive 
metabolite are usually used when we refer to “vitamin D status”. 
It was recently found that 1 alfa-hydroxylase is also produced in other tissues, then kidneys, 
but it is not regulated by PTH. Probably it is regulated by local tissue cytokines and growth 
factors and therefore, 1,25 (OH)2D production is small and dependent on the amount of 
available 25(OH)D [16].  
One may ask why we call vitamin D a “vitamin”? Why don’t we call it a “hormone”? 
1,25(OH)2D is according to existing definitions a genuine lipophilic hormone. It has its target 





specific qualities [17] and the action in target tissues (e.g. enterocytes) is mediated through 
the vitamin D receptor (VDR). Furthermore, there are also not bound fractions of circulating 
25(OH)D. Less then 1 % of total amounts of vitamin D metabolites are circulating as free 
steroids. So, we can see that vitamin D possesses all the propensities of a conventional 
hormone. This fact makes it even more interesting and tempting to explore novel effects of 
this phenomenal vitamin. 
Now some facts about VDR. Receptors are essential in normal hormone functioning. VDR is 
present in the most tissues and cells in the human body [16, 18]. That is consistent with our 
hypothesis of vitamin D`s role in extraskeletal health. The main physiologic function of VDR 
is promoting calcium and phosphorus absorption in enterocytes in the small intestine, through 
the interaction with 1,25(OH)2D [11] . Furthermore, through the interaction between VDR 
and 1,25(OH)2D in bone cells, immature preosteoclasts are converted to mature osteoclasts 
[19]. The mature osteoclasts stimulate the desorption of calcium and phosphorus from the 
bone (bone resorption) and hence repletion of serum calcium. In the kidneys, 1,25(OH)2D 
through VDR stimulates calcium reabsorption from the glomerular filtrate. Moreover, VDRs 
were also found in other tissues and organs (with no obvious physiological function of 
mineral balance maintaining), such as central nervous system, vascular smooth muscles, 
prostate cells, epithelial cells in breast glands, blood cells and tissue macrophages [16, 18]. 
1,25(OH)2D was demonstrated to be synthetized in these tissues as well, according to 
available levels of circulation 25(OH) [5, 16].  
The biological actions of 1,25(OH)2D are mainly divided into two types: genomic and non-
genomic. The main effect of 1,25(OH)2D, the maintaining of calcium homeostasis, is a 
genomic action. Briefly, genomic effects are mediated through regulation of transcription of 
genes in the target cells, which is facilitated by the VDR, a ligand activated transcription 





element or that are influenced indirectly, possibly by epigenetics, to control a substantial 
amount of genes across the genome [20]. The majority of regulated genes are related to 
calcium metabolism, but several other biological actions are considered. For example, 
inhibiting cellular proliferation, inducing terminal differentiation, inhibiting angiogenesis, 
stimulating macrophage cathelicidin production, stimulating insulin production, inducting 
apoptosis, inhibiting renin production [5, 21]. 
1,25(OH)2D has also non-genomic effects, but the mechanism of this is not fully understood. 
It is well documented that 1,25(OH)2D can exert rapid actions at the cellular level, 
independently of gene expression. Non-genomic effects include the opening of ion channels, 
the induction of second messenger’s molecule, such as mitogen activated protein kinases 
(MAPK), secretion of hormones (e.g. insulin), mediating the effects of growth factors and 
cytokines by altering either their cytosolic signaling pathways or the activity of their target 
transcription factors [22].  
The biochemical elaborations and physiological actions described above provide quite solid 
plausible biological mechanisms for the hypothesis that vitamin D is involved in a number of 
nonskeletal health related outcomes.  
 
 1.2 What are the optimal (sufficient) serum 25(OH)D levels? 
It is an essential question. The answer depends on what we want to prevent/cure? 
Alternatively, what effect do we want to receive? Still today, after many decades with 
massive vitamin D research, we basically know only one thing: the approximate levels of 
serum 25(OH)D in order to prevent rickets and/or osteomalacia (serum 25(OH)D >20 
nmol/L). Internationally, there is no consensus on what levels of vitamin D that should be 





clinical practice we follow the Nordic nutritional recommendations: serum 25(OH)D<25 
nmol/l is considered deficiency, levels from 25- to 50 nmol/l suboptimal, and >50 nmol/l to 
be optimal levels of serum 25(OH)D [25]. 
These recommendations were proposed based on current knowledge of an inverse association 
between serum PTH and serum 25(OH)D. Previous studies demonstrated that serum PTH 
achieved plateau levels (steady-state) in subjects with serum levels of 25(OH)D  between 20 
and 40 ng/ml (multiply with ~2,5 to convert to nmol/L) [26-28]. 
It is important to point out that to current date it is unknown what is the highest (or lowest) 
optimal level of serum 25(OH)D in order to prevent extraskeletal health outcomes. The 
increasing amount of published RCTs has not contributed to any consensus. It is worth 
mentioning, that there are studies with hard end-points such as mortality, cardiovascular 
mortality and cancer risk indicating that serum 25(OH)D levels as high as >100 nmol/l might 
be beneficial [23, 29, 30]. On the other hand, the U-shaped association between serum 
25(OH)D levels and extraskeletal outcomes has recently been described [31-34]. U-shaped (or 
sometimes also called J-shaped) association means that adverse/non-desirable effects on 
health are recorded in subjects with both extremely low and extremely high serum 25(OH)D. 
This emerging evidence is hard to ignore and this uncomfortable fact leaves us at the point 
where we started: what are the optimal serum 25(OH)D levels? 
Levels of serum 25(OH)D and the importance of the different vitamin D sources are 
dependent on different factors. One of most important sources of vitamin D is the epidermal 
production in the skin under sunlight exposure. The minimal erythema dose of UV radiation 
leading to the amount of vitamin D produced in the skin is equivalent to ingesting between 
10.000 and 25.000 IU of cholecalciferol [11]. Skin production of vitamin D depends on a 
variety of factors like skin pigmentation, age, clothing coverage and topical application of 





of the year. Above and below latitudes of approximately 33º, vitamin D3 synthesis in the skin 
is very low or absent during most of the winter [11, 12, 35, 36]. In North Norway (69 º North) 
sufficient UVB radiation for dermal vitamin D production is only available from the middle 
of March to the end of September [37]. 
Enteral intake of vitamin D containing foods and supplements is one of the most important 
sources of vitamin D in Norway in general and in North Norway in particular. Normally, an 
affordable Norwegian diet seldom contains enough vitamin D [38] to meet the requirements 
of 400 IU/day suggested by the Nordic Nutrition Recommendation working group [39]. 
Institute of Medicine of the National Academies recommends intake of 400-600 IU vitamin D 
daily, which is assumed to be associated with a predicted mean circulating 25(OH)D level of 
59 nmol/L in all age groups [40]. 
Intake of vitamin D supplements is therefore recommended and encouraged. Supplementation 
could be administered daily, weekly, monthly, or every 4 months to sustain serum 25(OH)D 
concentration >50 nmol/L [5]. 
What else may influence serum 25(OH)D levels? It is of course important to mention genetic 
variations in cholesterol metabolism, which have been shown to affect the production of 
vitamin D3 by limiting the amount of available 7- dehydrocholesterol [41]. Genetic 
differences in the VDR is associated with low serum 25(OH)D levels with potential clinical 
outcomes [41-44]. Genetic mutation of the cyp24p1 reduces the catabolism of 25(OH)D and 
1,25(OH)2D and may lead to infantile hypercalcemia [45]. 
Moreover, diseases and conditions affecting the gastrointestinal (GI) tract (e.g. celiac disease, 
malabsorption, Crohn`s disease of small intestine, post-bariatric surgical conditions with 





difficulties) may lead to substantially decreased absorption of orally consumed vitamin D [46-
48].  
 
1.3 Vitamin D and extraskeletal health. Metabolic disorders and inflammation 
Recent meta-analyses and systematic review studies indicate that vitamin D insufficiency is 
associated with higher risk of all elements of the metabolic syndrome like cardiovascular 
disease [49, 50], hypertension [51], obesity, insulin resistance [52, 53] and T2DM [54] .  
Vitamin D`s possible cardioprotective propensities and anti-inflammatory effects are 
suggested by the recent in vitro studies in which low 25(OH)D levels influenced the activity 
of macrophages and lymphocytes in atherosclerotic plaques and thus promoting chronic 
inflammation in the artery wall [55]. Moreover, the in vitro results indicate that 1,25(OH)2D 
inhibited foam cell formation and, hence, stimulated angiogenesis in endothelial colony-
forming, and the mechanisms behind that are most likely an elevation in vascular endothelial 
growth factor expression and pro-matrix metalloproteinase-2 activity [56]. Since arterial 
plaques and endothelial dysfunctions are among the most documented causes of CVD (e.g. 
myocardial infarction, angina, stroke and arterial insufficiency in lower extremities 
(claudication intermittens)), altered vitamin D status may have a plausible biological 
mechanism in CVD, according to the studies cited above. Furthermore, low serum 25(OH)D 
levels may contribute to an increased risk of CVD through hypertension (another well-known 
risk factor of CVD) because low serum 25(OH)D levels have been associated with an 
increased activation of the renin-angiotensin system, and thus contributing to elevated blood 
pressure [57, 58]. However, interventional studies with vitamin D supplementation have not 





According to recent in vivo studies insufficient vitamin D status is suggested to impact 
glucose tolerance and type 2 diabetes through various mechanisms [61, 62]. The VDR and 1-
alfa-hydroxylase are present in the pancreatic β-cell [63]. Stimulation of pancreatic islets in 
animal models demonstrate increased insulin secretion after addition of 1,25(OH)2D to the 
culture medium [64, 65]. Another potential explanation for these findings is VDR responsive 
action on the human insulin gene promoter [66]. Active vitamin D metabolite may also 
modulate β-cells growth and differentiation [54]. The vast majority of observational studies 
have supported these experimental results [67-69], but not all [70]. However, the well 
accepted conclusion of these studies is that genetic polymorphisms of VDR, enzymes 
responsible for vitamin D conversions into the active metabolite, and VDP may predispose to 
T2DM [65]. Altered metabolic profile in general, and  insulin resistance in particular may also 
be exaggerated because of chronic inflammation, due to possible effects of insufficient 
vitamin D status on proinflammatory cytokines like IL-6 and TNF-α, and low grade 
inflammation markers, such as hs-CRP [71]. However, a Mendelian randomization study on 
vitamin D and CRP did not find evidence for a causal relationship [72].  
The association between low serum 25(OH)D concentrations and decreased insulin sensitivity 
was found to be stronger in overweight individuals than in normal-weight individuals [73]. 
The storage of vitamin D in fat tissues may result in insufficient vitamin D bioavailability for 
influencing pancreatic β-cell function or activating VDRs, thereby increasing the risk of 
adverse glycemic outcomes [68]. Moreover, the clinical importance of proinflammatory 
cytokines-metabolic disease association (and that the association exists per se) has been 
demonstrated in weight loss intervention studies, where obese subjects showed reduction in 
IL-6 and TNF-α concentrations along with corresponding improvement of the metabolic 





Furthermore, IL-6 is produced not only by T lymphocytes but also by adipocytes and 
increased production of IL-6 inhibits adiponectin gene expression in cultured adipocytes [75]. 
Adiponectin has been suggested to have anti-atherogenic and anti-inflammatory propensities, 
it is also considered to have beneficial effects on glucose metabolism and lower levels of 
adiponectin are associated with insulin resistance and metabolic syndrome [76, 77]. Deranged 
levels of IL-6 may therefore contribute to endothelial dysfunction, thus playing an important 
role in the development and progress of CVD and metabolic conditions (e.g obesity and 
T2DM). Similar properties have been described for TNF-α which has even been called an 
“adipokine”, and in addition to possible production of cytokines in the adipocytes, there is 
also an infiltration of adipose tissue with inflammatory cells like macrophages [78, 79]. 
As mentioned above, observational findings are by no means proof of causality. To date, there 
are only few RCTs with T2DM and other metabolic disorders as primary outcomes and 
cholecalciferol as the treatment arm. Interestingly, those studies have as yet failed to 
demonstrate any beneficial effect on glucose metabolism, insulin resistance [80, 81] and on 
prevention of T2DM [82, 83].  
 
1.4  Vitamin D and extraskeletal health. Immune system 
We mentioned previously that the impact of vitamin D in inflammation might play a role in 
the development and progress of metabolic conditions. Interestingly, the association between 
vitamin D status and immune-mediated conditions like infections [84], autoimmune and 
allergic diseases [85] has also been well-studied during the past few decades. Three important 
discoveries, that were made in the last 25 years, suggesting the potential role of vitamin D and 
its active metabolite 1,25(OH)2D in the modulating of immune response are particularly 





inflammatory cells [86], secondly, the ability of 1,25(OH)2D to inhibit T-cell proliferation 
[87] and at last, but not in the least, the ability of disease activated macrophages to produce 
1,25(OH)2D [88]. 
Vitamin D and innate immunity.  
Innate immunity (also called non-specific immunity or in-born immunity) is the immune 
responses not specific to a particular pathogen. The innate immunity consists of a group of 
specific proteins, receptors and phagocytic cells that recognize the conserved features of 
pathogens and could be quickly activated in order to destroy the pathogens. The main 
pathway in innate immune response is the activation of toll like receptors (TLRs) in 
polymorphonuclear cells, such as monocytes and macrophages [89]. Involvement of vitamin 
D in this pathway has recently been described. Thus, pathogen/invader activates TLR 
signaling pathway in macrophages, which leads in turn to the transcriptional induction of 
VDR and CYP27B expression. Circulating 25(OH)D binds to plasma DBP, then enters 
macrophages and is converted to 1,25(OH)2D by mitochondrial CYP27B, and can retain 
VDR in the cell [90]. Once bound to VDR, 1,25(OH)2D is able to act as a transcriptional 
factor leading to the induction of cathelicidin synthesis, one of the antimicrobial peptides [91]. 
Incorporation into phagosomes containing internalized pathogen/invader enables cathelicidin 
to function as an antibacterial agent. As well as upregulating cathelicidin expression, 
macrophage synthesis of 1,25(OH)2D can also facilitate negative autoregulation, firstly via 
increased expression of the feedback enzyme CYP24A, and secondly via downregulation of 
TLR expression [90]. 
Vitamin D and adaptive immunity.  
Adaptive immunity, as opposed to innate, responds to a specific pathogen/invader (bacteria, 





agent and destroys them when they attack again. Adaptive immune responses, again unlike  
innate responses, are rather slow on the primary exposure to invader/pathogen, as specific 
clones of T and B lymphocytes have to be activated and expand. Macrophages and mature 
dendritic cells (DCs) can induce both T lymphocyte mediated and B lymphocyte mediated 
immunity by internalizing and processing invaders/pathogens. Macrophages and mature DCs 
also express the vitamin D-activating enzyme CYP27B and hence are able to synthetize 
1,25(OH)2D from inactive metabolite, 25(OH)D [92]. In turn, 1,25(OH)2D synthesized this 
way can act on activated B lymphocytes and activated T lymphocytes, which express 
abundant VDR. Moreover, 1,25(OH)2D inhibits differentiation of DCs and decreases T 
lymphocytes proliferation and activation by increase of the synthesis in the Th2 cells of  anti-
inflammatory cytokines IL-10, IL-4, IL-5 and inhibiting the synthesis in the Th1 cells of 
proinflammatory cytokines IL-2, IFN-γ and TNF -α [92, 93]. Due inhibition of Th1 cells 
vitamin D might be involved in the prevention of several autoimmune diseases such as 
multiple sclerosis (MS), rheumatoid arthritis (RA), type 1 diabetes (T1DM) and inflammatory 
bowel disease (IBD) [94]. Dysregulation of Th2 cells may in turn lead to development of 
allergic diseases, including asthma, allergic rhinitis and atopic dermatitis [90, 95]. 
B lymphocytes play a key role in adaptive immunity through the production of antibodies 
towards specific antigens. The vast majority of pathogens/invaders are able to express 
antigens (proteins and polysaccharides, and less frequently lipids), which in turn are triggers 
for the activation of B lymphocytes and adaptive immunity. B lymphocytes express the VDR 
and CYP27B1 event under non-activated (so-called resting) condition. Exposure of B 
lymphocytes to 1,25(OH)2D results in upregulation of VDR and CYP24A1 at the mRNA 
level [90]. In vivo studies revealed that active metabolite of vitamin D inhibits the generation 
of plasma cells and controls antibody expansion [96]. Moreover, 1,25(OH)2D inhibits the 





To summarize in short, there is a body of evidence that vitamin D is a biologically plausible 
mechanism in both innate and adaptive immunity; and insufficient vitamin D status might 
therefore influence the development and progress of such clinically relevant outcomes as 
infections, autoimmune diseases, allergies, and even malignancies, especially colorectal, liver 
and lung cancers [98, 99]. 
 
      1.5 Vitamin D and extraskeletal health. Carcinogenesis and aging 
Recent observational studies indicate that vitamin D deficiency is associated with increased 
incidence and prevalence of several types of malignancies [8, 100, 101]. Carcinogenesis is 
undoubtedly a multifactorial process, with involvement of the immune system, genomic 
changes/mutations, increased inflammation and so on [102, 103]. The interaction between 
inflammation and tumorigenesis is significant and present in very early stages; and also could 
be promoted to further carcinogenesis by genetic alterations [99]. Key factors in cancer-
related inflammation are transcriptions factors as NF-kappa B (NF-kB), activator of 
transcription 3 (STAT3) and major proinflammatory cytokines such as IL-1β, IL-6,IL-23 and 
TNF-α [99].  
Genetic alterations that cause tumorigenesis include the activation of various types of 
oncogenes like members of RAS and MYC family by mutation [104, 105], the inactivation of 
tumor-suppressor genes [99] and chromosomal rearrangement and shortening of telomere 
length. It has been recently established that telomere shortening plays an essential role in 
genomic instability, which in turn lead to carcinogenesis and malignant diseases [106, 107].  
Telomeres are repetitive nucleotide sequences located at the ends of chromosomes, telomeres 
do not participate in DNA replication or RNA synthesis. The main function of telomeres is to 





become shorter under each cell cycle (mitosis) and when a sufficient number of telomeres 
become critically short, apoptosis and cellular aging will be triggered with cell death as the 
inevitable result. Telomerase, a cellular enzyme, protects telomeres and maintains telomere 
length at equilibrium. Telomere dysfunction and disrupted genomic integrity are therefore the 
main genomic factors leading to aging and death at the cellular level [107, 109]. What about 
clinical consequences? Recent studies demonstrate that telomere shortening is frequently 
associated with higher risk of several age related diseases and conditions, such as CVD [110], 
different types of malignancies [111, 112] and last, but not  least, dementia [113, 114].  
Interestingly, both the telomere shortening process and increased telomerase activity are 
present in tumor cells, which is constantly in the uncontrolled mitosis; thus it is tempting to 
suggest that telomere dysfunction may not be only hallmark of cell aging but also one of the 
plausible mechanisms leading to unlimited cell proliferation and eventually tumorigenesis 
[107].  
In a research setting, it is usual to measure the telomere lengths in the blood cells, for 
instance, in leukocytes. It is considered the most convenient method, which does not involve 
unnecessary discomfort in the study participants, except for venous blood sampling. It is 
worth mentioning that with the appropriate laboratory method and reagents, one can measure 
telomere length in other cells than leukocytes, for instance in the epithelium; but in the setting 
of observational studies when the aim is to examine a substantial number of subjects, analysis 
of leukocyte telomere length (LTL) is used most frequently. 
Age is, of course, a well-established factor associated with telomere shortening. However, age 
is a non-modifiable factor and for us, clinicians, there is little to do when dealing with aging 
patients. Another non-modifiable factor, known to be associated with shorter telomeres is a 
non-Hispanic white race/ethnicity [115], to which the majority of the Scandinavian population 





influence telomere length. Environmental factors, dietary factors, such as increased energy 
consumption and the intake of high-sugar foods have been linked to shorter telomeres [116]. 
Thus, modifying t conditions and factors such as poor diet, overweight and obesity, one may 
prevent exaggerated telomere shortening [117-119]. Vitamin D insufficiency is one of these 
modifiable factors associated with increased age related disease, including premalignancies 
and cancer [8, 100, 101]. It  has recently been  linked to shorter LTL and we found it worth 
exploring further. 
Among other mechanisms, which might involve vitamin D in tumorigenesis, NF-κB signaling 
pathway is worth mentioning. Thus, there is an evidence from the in vitro studies that 
1,25(OH)2D may downregulate the NF-κB pathway and as a result lead to decreased 
proliferation of malign cells [120, 121]. Moreover, the possible antiproliferative effect of 
vitamin D might also be multifactorial; due to an effect on many genes that in turn regulate 
active proteins and pathways, such as E2F transcription factors, cyclin-dependent kinase 
activity, c-myc expression, transforming growth factor beta (TGF-β) signaling pathway, and 
prostaglandin signaling [122]. And finally, active metabolite of vitamin D has been shown to 
reduce the expression of telomerase reverse transcriptase (TERT), hence mitigating the 
telomerase activity, which is frequently elevated in the most of malignant cells [123]. 
 
1.6  Summary 
The rates of CVD, metabolic diseases and malignancies have indeed reached the pandemic 
levels [124], especially in the industrialized countries with rapidly aging populations and 
tremendously augmenting health costs. Though the vast majority of risk factors are well 
established, and the healthcare funds are generous in the western countries, the prevalence of 





associated with these conditions. Altered vitamin D status (e.g. insufficient levels of serum 
25(OH)D) is suggested be one of them. Through mediating the inflammation processes and 
influencing the human genome, vitamin D status might be involved in the development of 
clinically significant outcomes, such as CVD, obesity, T2DM and even carcinogenesis. Many 
questions remain to be answered, based on the findings from large observational studies 
and/or meta-analyses. After many years of a “vitamin D research rush” we still don’t know 
whether trying to increase serum 25(OH)D (and in that case, to what point) by means of high 
doses of cholecalciferol supplementation or solar exposure will give us clinically relevant 
health benefits. 
Our scientific work combines both epidemiological ways to study the relationship between 
the exposure and the outcome, observational and interventional. We hope that we would be 
able to approach some answers. 
 
 
2 Aims of the study 
The overall objective of this thesis is to investigate the association between serum 25(OH)D 
levels and some biomarkers of health related outcomes (e.g. inflammation and 
carcinogenesis). We have tried to investigate the possible associations from  both   
perspectives: observational (with the use of large population-based studies) and causal (with 
the use of RCTs).  
This dissertation consists of three independent projects/three papers. We used the Tromsø 
study and the U.S. NHANES as observational studies and the RCT studies. We used  ancillary 
studies to the RCTs with metabolic diseases as primary outcomes (obesity and T2DM). These 





Briefly, the aims of the subprojects were: 
- to investigate the association between serum 25(OH)D concentrations and levels of 
proinflammatory cytokines IL-6 and TNF-α in overweight subjects 
- to investigate the effect of vitamin D (cholecalciferol) supplementation on 
proinflammatory cytokines IL-6 and TNF-α in overweight subjects 
- to investigate association between serum 25(OH)D concentrations and hs-CRP, as a 
marker of low grade inflammation 
- to investigate if the supplementation with cholecalciferol reduces the serum 
concentration of hs-CRP during 5-year intervention   
- to examine the association between serum 25(OH)D concentrations and LTL, as a 
marker of carcinogenesis and aging. 
 
 
3 Methodological highlights and considerations 
A detailed descriptions of study designs, inclusion and exclusion criteria, intervention period, 
endpoints, physical and laboratory measurements and statistical tools are available in the 
individual papers. In this paragraph, we will try to give a brief description of the study 
population with an emphasis on the unique methods and analyses used in this work. The 
short-comings of ours studies will also be described in detail below. 
 





The municipality of Tromsø (Tromsø  69°40′58″N 18°56′34″E) is situated at the northern 
coast of Norway (Picture 1). The population has increased annually with approximately 1000 
inhabitants during past decade, and the present population (per 01.01.2017) is 74.541 
inhabitants [125]. The demographics is presented in Figure 1.  
Figure 1. The demographics of the Municipality of Tromsø. Data presentation is the courtesy 
of Central Bureau of Statistics. 
 
 
The population of the municipality of Tromsø is composed predominantly of subjects of 
Norwegian origin, in addition to a certain percentage of subjects of Sámi ancestry. Among 
foreign nationals or citizens of foreign decent, Polish, Swedish, Russian, German and Somali 





Figure 2. The distribution of foreign nationalities in the Municipality of Tromsø. Data 







The Tromsø Study is a longitudinal population-based study, conducted by the University of 
Tromsø in cooperation with the National Health Service, with the first survey in 1974. It is the 
largest population-based study in North Norway. It was designed to investigate lifestyle 
factors related to CVD in males. The main original objective was to find out the cause of the 
high prevalence of CVD in Northern Norwegian men and if there were some ways to prevent  
further increment [126]. The following surveys have also included women and other clinical 
outcomes such as endocrinological, neurological, dermatological, gastrointestinal and 
psychological diseases have also been investigated, and a wide array of possible causes and 
confounders have been included [127].  
     We used the data from the sixth Tromsø Study. The sixth Tromsø study was performed in 
2007 - 2008, and 9.625 men and 10.137 women, aged 30-87 years were invited to participate. 
All invited subjects received the information brochure (Appendix 1) and the questionnaire 
(Appendix 2). Among those, 6054 men and 6930 women attended the study, creating the 
participation rate of 62,9% and 68,4%, respectively. 
At the first visit, the participant’s medical histories were collected and they had a brief clinical 
examination (height and weight, blood pressure, waist and hip circumferences, as well as one 
blood sample was drawn). The participants were also asked to complete an additional 
questionnaire (Appendix 3). They were allowed to take the questionnaire home, complete it 
there, and return it by mail in the enclosed envelope. The blood samples, which were drawn at 
the examination, was later analyzed for serum 25(OH)D, Hba1c and hs-CRP. 
Since the serum 25(OH)D assay discrepancy for smokers versus non-smokers was early 
demonstrated [128], only non-smokers were included in our study (n=10.118). 
One of the main limitations in our observational study was that we were not able to cross 





nonsteroidal anti-inflammatory drugs (e.g. NSAIDS) or had any active inflammatory 
conditions (e.g. infection, latent autoimmune disease). This data could be important, since the 
outcome of our observational study is the association between serum 25(OH)D and 
inflammatory biomarkers. Moreover, we did not have access to the data on physical activity, 
which is also an important factor, while investigating exposure-outcome association regarding 
inflammation. However, we feel that excluding smokers added strength to our study as we 
eliminated smoking as a confounder in the investigation of the association between serum 
25(OH)D and hs-CRP. 
 
3.2 Observational Study. The U.S. National Health and Nutrition examination 
Survey (NHANES). Paper III 
NHANES is a program of studies designed to assess the health and nutritional status of adults 
and children in the United States. The background and historic facts are available at 
https://www.cdc.gov/nchs/nhanes/about_nhanes.htm. The survey is unique in that it combines 
interviews and physical examinations. NHANES is a major program of the National Center 
for Health Statistics (NCHS), and a part of the Centers for Disease Control and Prevention 
(CDC), which has the main responsibility to produce vital, and health statistics for the US 









Figure 3. The demographics of the US per 31.12.2016. The data presentation is the courtesy 
of the U.S. Census Bureau.  
 
The population distribution by race/ethnicity is demonstrated in Table 1. 
Table 1. The population distribution by race/ethnicity in the U.S. Data presentation is the 
courtesy of the Henry J. Kaiser Family foundation. Timeframe 2015. 
Race/ethnicity % of total population 
Non-Hispanic white 61 
Non-Hispanic black 12 
Hispanic 18 
Asian 6 
American Indian/Alaska Native 1 
Native Hawaiian/other Pacific Islander 0 







The US population is undoubtedly very diverse. This diversity is not only reflected by several 
races/ethnicities, but also in wealth and poverty levels and extreme social inequality. The U.S. 
Census Bureau's poverty threshold for a family with two adults and one child was $19,078 in 
2015. Figure 4 demonstrates the distribution of poverty rates in the U.S. 
Figure 4. Distribution of poverty by race/ethnicity. Data is the courtesy of Federal Safety Net. 
 
The NHANES program began in the early 1960s and has been performed as a series of studies 
focusing on different populations and/or health outcomes. In 1999, the survey became a 
continuous program and the focus changed more towards a variety of health and nutrition 
measurements to meet the emerging needs of the society and the healthcare system. In brief, 
the NHANES interview includes demographic, socioeconomic, dietary, and health-related 
questions. The examination component consists of medical, dental, and physiological 
measurements, as well as laboratory tests administered by highly trained medical personnel. 
The main objective of NHANES is to determine the prevalence of major diseases and risk 





status and its association with health promotion and disease prevention. NHANES findings 
are also the basis for national standards for measurements of height, weight, and blood 
pressure. Data from this survey are available for public access for researchers worldwide 
(https://www.cdc.gov/nchs/nhanes/index.htm) and is widely used in epidemiological studies 
and health sciences research. A quick search on https://www.ncbi.nlm.nih.gov/pubmed/ 
reveals that NHANES based studies embrace over 30.000 publications. The strategies of the 
National Center for Health Statistics in general and NHANES program in particular help to 
develop adequate public health policy, direct and design healthcare programs and services, 
and expand the current health knowledge not only for the US population, but also for 
humanity as a whole. 
 NHANES data is unique and represents the epidemiological state-of-the-art. The main 
difference from other large epidemiological studies (for instance our local Tromsø study) is 
that the data are obtained by using a complex, multistage probability-sampling design to 
select participants, representative of the civilian, non-institutionalized U.S. population. The 
continuous NHANES refers to the 2-years cycles of data produced since 1999. Basically, it is 
the mathematically computed sample, composed of approximately 10.000 subjects per cycle, 
which is representative for the entire US population. In other words, the computed sample is 
demographically, ethnically and income-wise more or less similar to the total population of 
the U.S. (see figures 3 and 4, and Table 1). The details of this complicated sample estimation 
and weighting are available on https://wwwn.cdc.gov/nchs/data/series/sr02_159.pdf.  The 
representativeness of the samples and great user-friendly public accessibility are the huge 
advantages of NHANES. However, we need to mention some minor limitations. Firstly, all of 
the dietary data, including intake of diary products, dietary supplements and the data on 





which was not cross-checked with tax reports. Secondly, self-reported diseases are not cross-
checked with patient records. 
 The continuous NHANES refers to the 2-years cycles of data produced since 1999. In paper 
II we used the data from the continuous NHANES cycles 2001-2002. An overview of this 
cycle is presented in Appendix 4. This particular cycle oversampled low-income persons aged 
60 years and over, persons of Hispanic, and non-Hispanic black race/ethnicity to obtain more 
accurate estimates in these populations. All respondents of this cycle aged ≥20 years were 
asked to provide DNA samples and consented specifically to future genetic research. Files 
providing genetic data were made available for public access in November 2014. There are 
some issues regarding methodological assessment of DNA and LTL in NHANES, which we 
feel need clearer acknowledgment here. DNA for LTL analyses was extracted from whole 
blood and stored at -80 °C using standardized procedures. The LTL assay was performed in 
the laboratory of Dr. Elisabeth Blackburn at the University of California, San Francisco, using 
the quantitative polymerase chain reaction (qPCR) method to measure telomere length 
relative to standard reference DNA (T/S ratio). The conversion from T/S ratio to kilobase pair 
(kb pair) was calculated based on a comparison of telomeric restriction fragment length from 
Southern blot analysis and T/S ratios using DNA samples from the human diploid fibroblast 
cell line IMR90 at different population doublings. The formula to convert the T/S ratio to kb 
pair was (3.274 + 2.413 × (T/S)). Since qPCR was not considered the gold standard of 
telomere length measuring, Cawthon [129] compared the standard method Southern blot and 
qPCR in 2002. In this study on 95 individuals, he found a strong correlation between these 
two very different approaches: correlation coefficient, r2, for the relationship of T/S ratio 
(from qPCR approach) to mean terminal restriction fragment (TRF) length (from Southern 






3.3  Interventional study. Tromsø vitamin D and obesity trial. Paper I 
Our work presented in Paper I is the ancillary study to the main 1-year RCT, Tromsø vitamin 
D and obesity trial. In this RCT, high dose vitamin D supplementation was tested against 
placebo and the primary end-point was weigh loss. Males and females 21-70 years old, with 
BMI between 28.0 and 47.0 kg/m² were recruited by advertisements in local newspapers and 
from the ambulatory department of internal medicine at the University Hospital of North 
Norway [130]. The study was registered at ClinicalTrials.gov (NCT00685594). The exclusion 
criteria were serum calcium >2.55 mmol/L, serum creatinine >129 μmol/L (men) and >104 
μmol/L (women). If serum calcium was 2.50-5.55 mmol/L, a measurement of serum PTH 
below 5.0 pmol/L was required. Other exclusions criteria were: known diabetes, active cancer 
or cancer diagnosed in the past five years, kidney stones, stroke or coronary heart disease in 
the past 12 month, pregnant or lactating women, women below 50 years without adequate 
contraception, planning a trip to a sunny location in the study period. Included subjects were 
required to withdraw from any current supplementation with calcium and/or vitamin D 
(including cod liver oil). Four hundred forty five subjects met the inclusion criteria and 332 
subjects fulfilled the intervention. The participants were randomized into three groups: DD 
group (two capsules of 20.000 IU cholecalciferol, per week), DP group (one capsule of 
20.000 IU cholecalciferol and one capsule of placebo, per week), and PP group (two capsules 
of placebo per week). They were all given supplementation with calcium 500 mg daily 
throughout the 1-year intervention period. Body measurements, estimates of insulin 
sensitivity (fasting insulin, HOMA-IR and QUICKI), as well as serum 25(OH)D, cytokines 
and h-s CRP were measured at baseline and at the end of intervention. The delta values were 
calculated to determine the changes (positive or negative) during the 1-year intervention.   
The main short-coming of this ancillary work is that the primary end point was weigh loss and 





point-weight loss. The inclusion criteria was therefore overweight and obese subjects and our 
results might not be applicable to the slimmer population. Moreover, we did not measure the 
cytokines in the intervals in between the baseline and the end of intervention, hence we could 
have missed the transient effects. And finally, all three groups received calcium 
supplementation, thus the potential effect of “pure” vitamin D supplementation  
is most likely missed. 
 
3.4  Interventional study. Tromsø vitamin D and T2DM trial. Paper II 
Our work presented in paper II is the ancillary work to the 5-year RCT, Tromsø vitamin D 
and T2DM trial. In this trial, it was investigated whether high dose vitamin D 
supplementation has any effect on the prevention of T2DM. A more detailed description is 
available elsewhere [83]. Briefly, subjects for this study were recruited mainly from the sixth 
Tromsø study, the methodological considerations for which were described in detail above. 
Eligibility criteria were: age 21-80 years and impaired fasting glucose (IFG) (fasting glucose 
>6.0 mmol/L and < 7.0 mmol/L) and/or impaired glucose tolerance (IGT). IGT was defined 
as 2-hours serum glucose >7.7 mmol/L and <11.1 mmol/L on oral glucose tolerance test 
(OGTT) with 75 g glucose combined with a fasting glucose < 7.0 mmol/L.  The exclusion 
criteria were: a history of coronary infarction, angina pectoris, stroke, sarcoidosis, cancer in 
the preceding 5 years, renal stones, nut allergies or reduced kidney function (serum creatinine 
>125 μmol/L in men and 105 μmol/L in women). Use of weight reducing drugs or 
antidepressant medications, pregnancy and lactation were also exclusion criteria, and females 






All participants were randomized into two groups: high dose vitamin D supplementation (1 
capsule with cholecalciferol 20,000 IU per week) or identical-looking placebo capsule 
containing arachis oil per week. The medications were provided for six months with all 
necessary information about intake of one capsule per each week. The subjects were not 
allowed to take vitamin D supplements (including cod liver oil) exceeding 400 IU per day. 
To keep all investigators blinded, all data were sent directly to the hospital's Clinical Research 
Unit where the data files were merged and coupled to the randomization code. The follow-up 
period was 5 years. The variables of interest for the present study were recorded each 12 
month. Delta values for hs-CRP were calculated for each year of intervention. 
    
 
4 Main results 
 
Paper I   Effects of a 1-year supplementation with cholecalciferol on interleukin-6, tumor 
necrosis factor-alpha and insulin resistance in overweight and obese subjects.  
In Paper I our aim was to examine the association between serum 25(OH)D and some 
proinflammatory cytokines (e.g. IL-6, TNF-α and hs-CRP) and if there is an effect of a 1 –
year supplementation with high dose cholecalciferol on these cytokines. The study was an 
ancillary study to another RCT where weight loss was the main primary outcome.  The 
subjects enrolled in this study were therefore overweight and obese.  
At baseline, serum 25(OH)D was significantly negatively associated with the measure of 
insulin resistance (HOMA-IR), adjusted for gender and smoking status, indicating that higher 
levels of 25(OH)D is associated with better insulin sensitivity (e.g. with an increase in serum 





associations were seen between serum 25(OH)D and levels of IL-6 and TNF-α, however the 
associations direction between serum 25(OH)D and levels of IL-6 was negative (linear 
regression coefficient of -0.09).  
There were no significant differences between the subjects in the DD, DP and PP groups 
before intervention.  When DD and DP groups were analyzed together, there were still no 
differences in baseline values (BMI, serum 25(OH)D, PTH, hs-CRP, IL-6, TNF-α, and insulin 
resistance measures HOMA-IR and QUICKI).  
After 1-year intervention, serum 25(OH)D increased and serum PTH levels decreased as 
expected in DD and DP groups as compared to PP group. Except for this finding, there were 
no significant changes in delta values for cytokines and insulin resistance measures in these 
three groups. However, after combining the DD and DP groups in one vitamin D group, the 
latter had a pronounced, but not statistically significant (P = 0.08) decrease in IL-6 and an 
elevation of hs-CRP at the end of the study when compared to the PP group. Neither measures 
of insulin resistance, nor TNF-α were influenced by a 1-year vitamin D supplementation. We 
concluded that vitamin D supplementation over a 1-year period had a lowering effect on a 
proinflammatory cytokine IL-6. However, the clinical impact is scarce since there was no 
corresponding effect on insulin sensitivity and other proinflammatory cytokines. 
 
Paper II  High-sensitivity CRP is associated with serum 25-hydroxyvitamin D levels, but is 
not affected by 5-year supplementation with cholecalciferol. 
In paper II our aim was to investigate the association between serum 25(OH)D and hs-CRP in 
the large observational study, the sixth Tromsø study, and in the smaller cohort of subjects 
with prediabetes. In the total study population of the sixth Tromsø study (n=10118), there was 





correlation coefficient r of −0.05 (P=0.001). In the linear regression model, after adjusting for 
age, sex, BMI, HbA1c and waist circumference, a 1 nmol/L increment in serum 25(OH)D 
resulted in a 0.02 mg/L decrease in hs-CRP (P=0.03). As there were significant interactions 
between BMI, serum 25(OH)D and sex, we performed a sex-stratified analysis. When 
analysing the genders separately, the negative association was statistically significant only in 
the women, resulting in a Pearson correlation coefficient r of −0.06 (P=0.001) and a β 
coefficient of −0.03 (P=0.03). In a smaller cohort of subjects with prediabetes (n=511), there 
were no significant correlations between serum 25(OH)D and hs-CRP. However, in a 
multiadjusted linear regression model there was a negative but not statistically significant 
association between serum 25(OH)D and hs-CRP, adjusted for age, sex, BMI, HbA1c and 
smoking, resulting in decrease in hs-CRP with 0.06 mmol/L with each increase of serum 
25(OH)D by 1 nmol/L. 
Furthermore, these subjects with prediabetes were randomized to either 20 000 IU 
cholecalciferol per week or placebo and followed up for 5 years. At baseline, there were no 
differences between the vitamin D group and the placebo group with regard to age (68±8 
years and 68±9 years, respectively) and sex (63% males and 60% females, respectively). 
There was also no difference in vitamin D supplement use (n=87 [34.0%] in the vitamin D 
group versus n=92 [36.1%] in the placebo group). The effect of intervention was studied by 
the analysing differences between delta values of hs-CRP for each year of intervention and 
with the logistic regression model, with hs-CRP decrease (yes/no dichotomous variable) and 
type of intervention(cholecalciferol/placebo) as a predictor, adjusted for age, sex, BMI, 
HbA1c and smoking status at baseline). There were no significant differences between the 
vitamin D and placebo groups in delta values of hs-CRP during any part of the 5-year 
intervention. Interestingly, in contrary to what was expected, vitamin D intervention was 





however, the statistical significance of this observation was only seen for delta values at the 
second year. 
 
Paper III Serum 25-Hydroxyvitamin D has a modest positive association with leucocyte 
telomere length in middle-aged US adults. 
In Paper III our aim was to examine the association between serum 25(OH)D and LTL. LTL 
was measured in 4260 participants of different age groups. Three age groups were defined: 
young adults 20-39 years, middle-aged adults 40-59 years and older adults ≥60 years. There 
were no differences in serum 25(OH)D concentration between age groups. All of the age 
groups differed significantly in LTL, with the longest LTLs in adults aged 20-39 years. Only 
women aged ≥60 years had significantly longer LTL than men of the same age; otherwise, 
there were no significant differences in LTL according to sex in those aged 20–39 and 40–59.  
     In the whole study population, age and BMI had significant negative associations with 
LTL when adjusted for sex, race/ethnicity, serum 25(OH)D, total energy and sugar intakes, 
calcium intake, socioeconomic status, consumption of milk and supplements, and physical 
activity. Thus, an increase in age by one year was associated with 0.02 ± 0.001 kb pair shorter 
LTL (P < 0.001), and an increase in BMI by 1 kg/m2 was associated with 0.01 ± 0.002 kb pair 
shorter LTL (P=0.02). Furthermore, in the same multiple adjusted model, female sex was 
associated with 0.09 ± 0.03 kb pair longer LTL (P=0.02) as compared to male sex, and non-
Hispanic black race/ethnicity was associated with 0.10 ± 0.05 kb pair longer LTL (P=0.049) 
as compared to non-Hispanic white race/ethnicity. Serum 25(OH)D concentrations had no 
significant association with LTL in the whole population. 
     In age group stratified multivariate analyses, age was the only significant negative 





demonstrated a subtle, but statistically significant, positive association between serum 
25(OH)D and LTL after adjustments for age, sex, race/ethnicity, BMI, total energy and sugar 
intakes, calcium intake, socioeconomic status, consumption of milk and supplements, and 
physical activity . An increase in serum 25(OH)D concentration by 10 nmol/L was associated 
with 0.03 ± 0.01 kb pair longer LTL in the unadjusted model and with 0.03 ± 0.01 kb pair 
longer LTL in the multiple adjusted model. After sex stratification of the age group 40–59 
years, and after the multiple adjustments for other factors, the 25(OH)D–LTL association 
remained positive and statistically significant in both sexes (β of 0.03, P= 0.04 and β of 0.03 
P= 0.02, for men and women respectively). 
     Moreover, middle-aged participants with serum 25(OH)D concentrations considered 
optimal (25(OH)D ≥ 50 nmol/L) demonstrated significantly longer LTL than their 
counterparts with serum 25(OH)D concentrations < 50 nmol/L (5.90 ± 0.05 kb pair versus 
5.78 ± 0.05 kb pair, respectively, P = 0.03). When serum 25(OH)D was entered into the 
multivariate regression model as a dichotomous variable (< 50 nmol/L and ≥ 50 nmol/L) and 
adjusted for age, sex, race/ethnicity, BMI, and other factors, participants with serum 25(OH)D 
concentrations ≥ 50 nmol/L had 0.13 ± 0.04 kb pair longer LTL compared to their 
counterparts with serum 25(OH)D concentrations < 50 nmol/L (P = 0.01). 
 
5 General discussion of the main results 
 
Vitamin D, metabolic syndrome and inflammation. 
Overweight is a risk for all-cause mortality [131] and has become a pandemic in the last 





Chronic inflammation and proinflammatory cytokines CRP, IL6, TNFα are tightly associated 
with metabolic conditions like obesity, insulin resistance, endothelial dysfunction and CVD 
[133, 134] . Patients with T2DM also demonstrate deranged inflammatory profile with 
overproduction of certain proinflammatory cytokines [135]. 
Reduced concentrations of serum 25(OH)D and inadequate vitamin D status has recently been 
linked to proinflammatory conditions, such as metabolic syndrome [136] , CVD and 
atherosclerosis [137], insulin resistance and overweight [138, 139]. A body of evidence from 
associational studies has stimulated the further interventional research on vitamin D and 
prevention of these conditions. 
In Paper I we found a strong association between cytokines and metabolic syndrome 
parameters at the baseline of the RCT. This is consistent with results from earlier 
observational studies [140-143].  No significant correlation was found between 
proinflammatory cytokines and vitamin D, which is partly opposite to findings from some 
other studies. For instance, Peterson et al. studied 69 healthy women, aged 25-82 years with a 
wide range of serum 25(OH)D concentration, due to recruitment from both high and low sun 
exposed populations. In this study, the authors found that TNF-α was inversely related to 
serum 25(OH)D, while no significant association was found between serum 25(OH)D and 
other proinflammatory cytokines ( CRP, IL-10 and IL-6)[144]. It is interesting to note that 
mean serum 25(OH) D in our study was lower than mean serum 25(OH)D in women from 
UV low-exposed population in Peterson`s study (54.3 nmol/l versus 74.4 nmol/L, 
respectively), and certainly lower then mean serum 25(OH)D in women from UV high-
exposed population (126 nmol/L). At the same time in Peterson`s study serum levels of TNF-
α differed significantly between groups according to serum 25(OH)D status, and the high UV-
exposure group had significantly lower serum TNF-α levels than the low UV-exposure group 





TNF-α levels even higher than those from the low UV-exposure group in Peterson’s study 
(1.53 pg/ml), which might be explained by our subjects' overweight which is proinflammatory 
per se.  
In the RCT we found that vitamin D supplementation over a 12 month period had a lowering 
effect on IL-6, but no effect TNF-α or hs-CRP. Our findings are opposite to some other 
interventions, in which a beneficial effect of vitamin D supplementation on proinflammatory 
cytokines, TNF-α, IL-6 and IL-10 was described [143, 145, 146]. However, these studies 
were performed in highly selected groups of patients with type II diabetes, end stage kidney 
disease and colorectal adenoma. These diseases have more pronounced inflammation and 
adverse immune response, as compared to an otherwise healthy overweight population in our 
RCT. 
Despite evidence of IL-6 involvement in glucose metabolism [142] and findings of lowering 
of IL-6 under supplementation with vitamin D in previous RCTs [143] , we didn’t 
demonstrate any favorable effect of decreased of IL-6 during cholecalciferol supplementation 
on insulin sensitivity. Most likely the potential effects on insulin sensitivity could be 
mitigated by the fact that metabolic disturbances and inflammatory changes were not severe 
enough to be clinically significant.  
An unexpected finding in our paper I is increased hs-CRP after 12 months supplementation 
with high dose cholecalciferol. Interestingly, a similar finding is also present in our paper II. 
This is hard to explain. A possible explanation might be the parallel stimulation of protein 
synthesis (including acute-phase proteins) in the liver under the cholecalciferol treatment, and 
CRP is a protein which is predominantly synthesized in the liver [75]. Its worth mentioning 
that the similar finding in our paper II was only statistically significant after the second year 
of intervention and was further mitigated during the continued intervention. This finding is 





In Paper II we demonstrated a significant negative correlation between serum 25(OH)D and 
hs-CRP in the general non-smoking population in our observational study. The association 
was highly significant in females only after gender stratification. However, regarding our 
prediabetes RCT population, we did not find any significant association between serum 
25(OH)D levels and serum levels of hs-CRP. The supplementation with 20 000 IU 
cholecalciferol per week during 5 years period did not lead to any lowering effect on hs-CRP. 
Moreover, as mentioned above, after second year of intervention receiving the cholecalciferol 
treatment was associated with almost 50 % increased odds ratio of getting increased hs-CRP 
values.  
Some observational and interventional studies, unlike ours, show significant negative 
association between vitamin D and hs-CRP, and lowering effect of cholecalciferol on hs-CRP, 
but mostly in subjects with other proinflammatory conditions like cardiovascular disease, 
obesity and in the elderly [149-151]. Interestingly, this relationship was than stronger in those 
with lower levels of serum 25(OH)D or in those with higher serum levels of hs-CRP [152-
156]. This discrepancy can be explained by possibly higher expression of proinflammatory 
cytokines in vitamin D deficient subjects.  
The lack of an intervention effect in our paper II is not very unexpected, however, in regard to 
our study population. At baseline there was no significant association between serum 
25(OH)D and hs-CRP, while the direction of the association was nevertheless inverse. It is 
important to remember that study populations for our observational study and our RCT study 
were quite different. The RCT population included subjects with prediabetes and hence 
ongoing inflammation, though otherwise healthy. The drawback of the majority of RCTs is 
that they recruit highly specific populations with one or several diseases/conditions, on which 
we try to intervene. In our RCT the target population included subjects with prediabetes and 





been composed of generally healthy subjects from Tromsø municipality and the primary 
outcome was lowering of proinflammatory cytokines, the result might have been different.  
Summarizing, there is an association between serum 25(OH)D levels and proinflammatory 
cytokines (hs-CRP) in  the North Norwegian general population. A population with more or 
less optimal serum 25(OH)D levels (~50 nmol/L). However, long-term supplementation with 
high dose cholecalciferol in a vitamin D sufficient population, but with present metabolic 
conditions (e.g. obesity or prediabetes) does not lead to decrease in proinflammatory 
cytokines (Il-6, TNF-α and hs-CRP). Thus, the effect of cholecalciferol treatment on 
metabolic conditions with deranged inflammatory profile is uncertain and most likely 
minimal, if present at all.   
Vitamin D and Leukocyte Telomere Length 
Previous observational studies indicate that vitamin D deficiency is associated with increased 
incidence and prevalence of age-related diseases, such as CVD, cancer and autoimmune 
diseases [11, 18, 58] . Moreover, findings from the observational studies are supported by 
recent genetic research [157]. It is well established that telomeres shortening play an 
important role in carcinogenesis and are crucial for aging at cellular level [106]. Several 
studies from the past decade demonstrate that telomere shortening (for instance measured as 
LTL) is significantly associated with higher risk of CVD, dementia and inflammatory diseases 
[107, 110, 158] . 
Our study supports current knowledge on the associations between LTL and age, LTL and 
race/ethnicity on many points. However, our findings of the positive and significant 
association serum 25(OH)D-LTL in middle-aged adults were only in partially consistent with  
existing research. Thus, in the study based on Northern Finland Birth Cohort 1966, there was 





the Finnish study were 31 years old at the time of the study, and the small age range could be 
a possible explanation for the discrepancy between their results and ours. 
Other studies that found no association between serum 25(OH)D and LTL, were the studies 
by Julin et al.[160] and Liu at al.[161]. However, these studies were performed on highly 
selected populations and did not represent wide samples of participants across all age groups 
in human adulthood and diversity in race/ethnicities. 
To our knowledge, only one of these observational studies on white women with an average 
age of 59 years [162] found a significant positive association between serum 25(OH)D and 
LTL, and results that were similar to ours. In this study the highest quartile of serum 
25(OH)D (median concentration of 103 nmol/L) was associated with an almost 60% 
increased odds of higher LTL compared with the lowest quartile (median serum 25(OH)D 
concentration of 38 nmol/L). 
We also found significant associations between LTL and age, sex and BMI and these findings 
support knowledge about telomere shortening during aging, shorter telomeres in men than 
women and shorter telomeres in obese persons. 
Thus, our observational findings may be interpreted in two ways. Firstly, the genomic 
instability associated with decreased serum 25(OH)D levels may start in younger adulthood 
and targeting the sufficient/optimal vitamin D status, may prevent accelerating of the LTL 
shortening. Another interpretation may come from the perspective of an inverse causality. 
Thus, one can speculate that middle-aged persons with optimal vitamin D status have in 
general better health, lower incidence of chronic conditions and subsequently have lower 






With regard to vitamin D`s role in carcinogenesis, it is undoubtedly difficult to provide proof 
causality even though evidence from several upcoming RCTs show lower incidents of some 
cancer types under supplementation with vitamin D [165, 166]. Neither of these studies have 
incidence of malignant diseases as a primary outcome, the occurrence of malignancies were 
registered as secondary outcomes. Future studies are indeed needed to determine the effect of 
vitamin D in the prevention of malignancies. Nevertheless, we feel that our findings are 
important as they strongly support the biological plausibility of the latter hypothesis. 
 
 
6 Conclusions and future opportunities 
 
Our findings are partly consistent with other studies regarding a relation between serum 
25(OH)D levels and markers of inflammation, carcinogenesis and aging.  
- there is no statistical significant associations between serum 25(OH)D and levels of 
IL-6 and TNF-α in the overweight and obese subjects at the baseline of RCT, however 
the associations direction between serum 25(OH)D and levels of IL-6 is inverse  
- cholecalciferol supplementation (20 000 IU/weekly or 40 000 IU/weekly) tends to 
decrease the levels of IL-6 and does not affect TNF-α levels in overweight and obese 
subjects 
- there is a significant negative association between serum 25(OH)D concentrations and 
hs-CRP (a marker of low grade inflammation) in the non-smoking general population 
and this relation is independent of other factors. However, in subjects with 
prediabetes, there is no such significant association at the baseline of RCT 
- supplementation with cholecalciferol (20 000 IU/weekly during 5 years) does not 





- there is a significant positive association between serum 25(OH)D concentrations and 
LTL (a marker of carcinogenesis and aging) in middle-aged adults in the U.S. 
The observational studies were based on different populations, north Norwegian and 
American, which strengthens the legitimacy and eligibility of our findings. However, two of 
the RCTs which we performed and analyzed could not support the hypothesis that vitamin D 
supplementation can have a positive effect on inflammation markers. The main conclusion of 
this thesis is therefore that deranged vitamin D status is associated with increased levels of 
proinflammatory cytokines and marker of carcinogenesis and aging LTL, but since the 
beneficial effect of cholecalciferol supplementation was not evident, clinical importance and 
implication of this association is most likely scarce.  
The results of some large RCTs on the effect of vitamin D on clinically relevant outcomes 
have started to be published [167]. To our knowledge, the only clinical outcome which is 
demonstrated to be improved by high dose cholecalciferol supplementation is muscle 
strength, and as a result reduced fall frequency in the elderly [168]. The other extraskeletal 
benefits of vitamin D are yet to be confirmed. The different dosages of cholecalciferol and 
different administration intervals are also examined in ongoing studies. It might be also 
interesting to investigate if enteral cholecalciferol administration is equal in regard to 
biological and clinical effect as vitamin D received through skin as a result of UV radiation. 
To our knowledge, there are no ongoing RCTs focusing on this issue. However, it could be 
difficult to obtain the necessary permits from the ethics committees, as it would involve solar 
exposure. Future investigations are needed to establish the further extraskeletal clinical impact 
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Vil du være med i den 6. Tromsøundersøkelsen?
» viktig forskning
» undersøkelse av egen helse
» forebygging av helseproblemer
Hva er Tromsøundersøkelsen?
Tromsøundersøkelsen er et stort forskningspro-
sjekt. Opplysninger som samles inn skal brukes 
til å gi oss kunnskap som kan bedre menneskers 
helse. 
Den første Tromsøundersøkelsen ble gjennom-
ført allerede i 1974, og dette er den sjette i rekken. 
Et viktig mål med undersøkelsen er å få kunnskap 
om hvorfor noen blir syke mens andre beholder 
god helse gjennom livet.
Visste du at ..?
Den som deltar på Tromsøundersøkelsen får også 
en enkel undersøkelse av sin egen helse. 
Hva forskes det på i 
Tromsøundersøkelsen?
Tromsøundersøkelsen gjennomføres først og 
fremst for å kunne øke kunnskapen om de store 










Undersøkelsen vil også bli benyttet til forskning om 
bruk og effekter av legemidler, trivsel, livskvalitet, 
livsstil, døgnrytme, smerter, sosial ulikhet, fysisk 
aktivitet, kosthold, bruk av helsetjenester og alter-
nativ behandling.   Det vil også bli undersøkt om 
miljøgifter kan påvises i blodet og om disse inn-
virker på helsa. 
Videre vil det bli gjort forskning på kvinnesyk-
dommer, sykdommer i fordøyelsesorganer, allergi, 
nyrer og urinveier, nervesystemet, sanseorganer 









som følge av disse sykdommene eller tilstandene. 
En del av prosjektene vil spesielt undersøke sam-
spillet mellom arv, miljø, sykdom og helse. Til slike 
prosjekter vil det bli hentet ut DNA (arvestoff ) fra 
blodprøvene. 
Det er allerede planlagt mange forskningspro-
sjekter som skal benytte data fra Tromsøunder-




Ved å delta på Tromsøundersøkelsen er du med 
på å bidra til forskning om hvordan sykdom kan 
forebygges og behandles, hva som fremmer god 
helse, og hva som er årsak til helseproblemer. 
Hvorfor spør vi deg?
Alle som møtte til spesialundersøkelsene i 
Tromsøundersøkelsen i 1994 og 2001, og et tilfel-
dig uttrukket utvalg av personer som er over 30 
år og som er innbyggere i Tromsø kommune, blir 
spurt om å delta. 
Alle er viktige!
Hver deltaker er like viktig, enten du er ung eller 
gammel, frisk eller syk. Det har vært stort fram-
møte til de tidligere Tromsøundersøkelsene. Godt 
oppmøte er viktig for gode forskningsresultater. 
Det er en styrke for forskningen at de som har 
vært med i tidligere Tromsøundersøkelser møter 
fram på nytt.
Frivillig 
Det er frivillig å delta. Det vil ikke få noen 
konsekvenser for deg dersom du ikke deltar 
eller velger å trekke deg fra undersøkelsen på et 
senere tidspunkt. Du må ikke gi noen begrunnelse 
dersom du ønsker å trekke deg fra undersøkelsen. 
Visste du at ..?
Du kan delta på Tromsøundersøkelsen selv om 
det er deler av undersøkelsen du ikke ønsker å 
være med på. 
Din helse
Cirka fire uker etter undersøkelsen vil du få et brev 
med resultatene fra målinger av kolesterol og 
blodtrykk. Dersom det er nødvendig, vil du bli an-
befalt å ta kontakt med din fastlege. Det blir ikke 
gitt rutinemessig tilbakemelding om resultater av 
andre blodprøver eller målinger. 
Dersom resultatet av prøvene viser at det er nød-
vendig med oppfølging av lege eller henvisning 
til spesialist, vil du bli orientert om det. Ved behov 
for henvisning til spesialist, vi vil sørge for at slik 
henvisning blir sendt. 
Du kan reservere deg mot å få vite resultatene av 
prøvene dine. Men hvis et prøveresultat er slik at 
det er nødvendig med rask legebehandling, vil du 
uansett bli kontaktet.
Tromsøundersøkelsen er gratis. Trenger du videre 
undersøkelse / oppfølging av fastlegen eller i 
spesialisthelsetjenesten, betaler du vanlig egen-
andel.  
Slik foregår undersøkelsen
Sammen med dette informasjonsskrivet ligger 
det et ark med praktiske opplysninger og beskjed 
om hvor og når du kan møte fram. Her står også 
åpningstidene for undersøkelsen. Hvis du vil delta 
og den foreslåtte tiden ikke passer, kan du komme 
en annen dag. Du trenger ikke melde fra om dette 
på forhånd. 
Unngå før undersøkelsen
For at resultatene skal bli mest mulig korrekt, er 
det en fordel om du avstår fra alkohol og smerte-
stillende medisiner 12 timer før undersøkelsen. 
Påkledning
Vekt og høyde, liv- og hoftevidde måles med lett 
påkledning, men uten sko. For at det skal gå raskt 
å måle blodtrykk, er det en fordel om du har plagg 
som ikke strammer over armen og benet. Ha 
gjerne et kortermet plagg innerst.
Spørreskjema
Sammen med denne brosjyren har du fått et 
spørreskjema som du skal fylle ut og ta med til 
undersøkelsen. Hvis du er i tvil om hvordan du skal 
svare på et eller flere av spørsmålene, lar du det 
stå åpent. Personalet på undersøkelsen hjelper 
deg da med utfyllingen om du ønsker det.
Utfylte svar i spørreskjema er like viktig for forsk-
ningen som resultater fra blodprøver og under-
søkelser.
Regelmessig bruk av legemidler
Ved frammøte til undersøkelsen vil du bli intervjuet 
om hva slags legemidler du har brukt regelmessig 
de siste fire ukene, og om noen av de legemidlene 
du har brukt siste 24 timer. Navn på legemidler du 
bruker fast kan besvares i skjemaet på forhånd. Ta 
gjerne med deg legemidlene du bruker ved fram-
møte til undersøkelsen. 
Undersøkelser
Når du møter fram, vil kvalifisert helsepersonell 
veilede deg gjennom undersøkelsen og svare på 
spørsmål. Du vil bli intervjuet og få utlevert et 
nytt spørreskjema med en frankert svarkonvolutt. 
Spørreskjemaet kan også besvares mens du er til-
stede på undersøkelsen, og du vil kunne få hjelp 
underveis. Hver enkelt undersøkelse varer bare 
noen minutter. Totalt vil undersøkelsen vare cirka 
en time.
De måler høyde, vekt, hoftevidde og livvidde, 
de måler blodtrykket og tar blodprøve av deg. I 
tillegg vil følgende undersøkelser bli gjort:
Beintetthetsmåling (måling av beinmasse) 
i den ene armen med svake røntgenstråler.  
Målingene brukes til å undersøke risiko for 
beinskjørhet og brudd.
Bakterieprøve fra nese og hals fra om lag 
halvparten av deltagerne, for å se etter gule 
stafylokokker, en bakterie som normalt finnes 
på hud og slimhinner hos mennesker, men 
som i enkelte tilfeller kan forårsake alvor-
lige infeksjoner. Prøven gjøres med fuktet 
vattpensel.
Smertefølsomhet som måler hvordan kropp-
en reagerer på smerte.  Du blir bedt om 
å holde hånden i isvann i opptil 1 minutt.  
Underveis registreres blodtrykk og du angir 
hvor mye smerte du kjenner. Du kan ta hånd-
en ut av vannet før tiden er ute hvis det blir 
for ubehagelig.
Hårprøve.  Vi vil be om å få noen hårstrå for å 






Fysisk aktivitet og kosthold. Vi planlegger at  
utvalgte deltakere vil bli bedt om å registrere 
fysisk aktivitet (aktivitetsmålere som skritt-
tellere og lignende) og kosthold i en periode.
Blodprøver
Blodet fordeles på fem glass, men til sammen ut-
gjør det ikke mer enn 45 milliliter, som er mindre 
enn en tidel av det en blodgiver gir. For de aller 
fleste vil det være tilstrekkelig med ett stikk.  Disse 
analysene blir gjort:
Måling av kolesterol og andre fettstoffer, 
blodsukker, blodlegemer, stoffskifteprøver, 
hormoner, markører for betennelsesreaksjon-
er, allergi, mage- og tarmfunksjon, lever- og 
nyrefunksjon samt muskel- og beinmarkører.
DNA (arvestoff ) vil bli lagret til bruk i forsk-
ningsprosjekter som er omtalt i denne bro-
sjyren og som kartlegger sammenhengen 
mellom arv og miljø, sykdom og helse. DNA vil 
ikke bli brukt til andre formål enn forskning.
Miljøgifter, blant annet sporstoffer, spor-
metaller og organiske stoffer. Forekomsten i 
blodet skal sammenlignes med tilsvarende 
målinger i andre befolkninger. Forskere vil 
studere om miljøgifter kan påvirke helsa vår. 
Spesialundersøkelsen 
Når første del av Tromsøundersøkelsen er 
gjennomført, kan du bli forespurt om å delta i en 
eller flere deler av Spesialundersøkelsen noen uker 
senere. Over halvparten vil bli spurt om dette. Hele 





varigheten vil være avhengig av hvor mange deler 
du blir spurt om å være med på. Ved oppmøte til 
Spesialundersøkelsen vil det bli tatt ny blodprøve 
som skal brukes til samme formål som beskrevet 
for første del av undersøkelsen. Deler av blod-
prøven blir frosset ned for senere bruk i forskning 
som er beskrevet i denne brosjyren. 
Hvilke undersøkelser gjøres i 
Spesialundersøkelsen?
Ultralyd av blodårene (arteriene) på halsen. 
Undersøkelsen gjøres for å se etter for-
kalkninger og innsnevringer av årene.  
Undersøkelsen kartlegger også  blodforsyn-
ingen til hjernen.
Ultralyd av hjertet gjøres for å undersøke 
hjertets form og funksjon. 
Måling av beintetthet i rygg/hofte og  
kroppens fettmengde. Målingene brukes til 
å undersøke risiko for beinskjørhet og brudd, 
og for studier om sammenhengen mellom 
kroppsfett, beinmasse og brudd.
Fotografering av øyebunn. Fotografiet vil 
vise tilstanden for blodkarene i øyet som 
også sier noe om blodkarene i kroppen. Ved  
øyestasjonen tas fotografi av øyebunnen din. 
Deltagerne får en øyedråpe i hvert øye en 
tid før fotografering for at pupillene skal ut-
vide seg. Dette kan svi noe og synet kan for-
bigående bli noe uklart. Effekten går gradvis 
over, og etter en time er den borte. I tillegg vil 
det gjøres en enkel synstest som du vil få svar 
på umiddelbart.
Tester av hukommelse gjøres ved hjelp av 
enkle spørsmål og omfatter også evne til 
gjenkjenning av ord og grad av fingerbeve-
gelighet.
EKG og blodtrykk. EKG er en registrering av 
hjerterytmen som også kan gi informasjon 
om hjertesykdom. Ved registrering festes led-
ninger til kroppen. Blodtrykket måles både på 







Pusteprøve. Dette er en enkel undersøkelse 
av lungefunksjonen. Du skal puste så hardt du 
klarer gjennom et munnstykke. Hvor mye luft 
som blåses ut pr. sekund, er et mål på lunge-
funksjonen din.
Ny bakterieprøve fra nese og hals. Prøven 
utføres på samme måte som i første del av  
undersøkelsen. 
Urinprøve. Du vil bli bedt om å avlevere 
urinprøver fra de tre siste dagene før  
spesialundersøkelsen. Du gis alt nødvendig 
utstyr. Urinen blir lagret til bruk i forskning 
som er beskrevet i denne brosjyren.
For å sikre høy kvalitet på forskningsdata ønsker 
vi å undersøke et lite utvalg som møter til under-
søkelsen to ganger med circa en ukes mellomrom. 
De som er aktuelle vil bli forespurt om dette ved 
frammøte.
Nye prosjekter
Noen deltakere vil i ettertid bli spurt om å delta 
i videre undersøkelser.  Hvis dette gjelder deg, vil 
du få en forespørsel i posten. Du er ikke forpliktet 
til å delta selv om du har deltatt i andre deler av 
Tromsøundersøkelsen. Omtale av alle delprosjek-
tene finner du på nettsiden vår:
http://www.tromso6.no
Forsikring og finansiering 
Deltakere i Tromsøundersøkelsen er forsikret 
gjennom Norsk Pasientskadeerstatning.  
Tromsøundersøkelsen er finansiert av Uni-





Etikk, personvern og sikkerhet
Du kan være trygg på at informasjon som gis til 
Tromsøundersøkelsen vil bli behandlet med res-
pekt for personvern og privatliv, og i samsvar med 
lover og forskrifter. Alle medarbeidere som jobber 
med undersøkelsen har taushetsplikt. Opplysnin-
gene som samles inn vil bare bli brukt til godkjen-
te forskningsformål.
Alle opplysninger om deltakere vil bli lagret på 
datamaskin. Navn og personnummer blir fjernet 
og erstattet med en kode. Kodenøkkelen oppbe-
vares separat og kun noen få, autoriserte medar-
beidere har tilgang til denne. 
Den enkelte forsker får ikke tilgang til opplys-
ninger som gjør det mulig å identifisere enkelt-
personer. Hver enkelt deltaker har en rett til å vite 
hvilke opplysninger som er lagret om en selv.
For alle  prosjekter kreves det at prosjektlederen 
tilhører en kompetent forskningsinstitusjon.
Tromsøundersøkelsen har konsesjon fra Data-
tilsynet og er godkjent av Regional komité for  
medisinsk forskningsetikk, Nord-Norge.
Sammenstilling med andre registre
Opplysninger om deg fra den sjette Tromsøunder-
søkelsen kan bli knyttet sammen med opplys-
ninger fra tidligere Tromsøundersøkelser. For 
enkelte prosjekter kan det være aktuelt å sammen-
stille opplysninger om deg med opplysninger fra 
barn, søsken, foreldre og besteforeldre hvis disse 
har deltatt i Tromsøundersøkelsen.
For spesielle forskningsprosjekter kan det være 
aktuelt å sammenstille informasjon fra Tromsø-
undersøkelsen med nasjonale helseregistre som 
Reseptregisteret, Medisinsk fødselsregistrer, 
Kreftregisteret, Norsk pasientregister og Døds-
årsaksregisteret, og andre nasjonale registre over 
sykdommer som det forskes på i Tromsøunder-
søkelsen. 
I tillegg kan det være aktuelt å innhente helseopp-
lysninger fra primær- og spesialisthelsetjenesten 
til bruk i forskning på sykdommer og helsepro-
blemer som er nevnt i denne brosjyren, for 
eksempel hjerte-karsykdom, diabetes og bein-
brudd. I slike tilfeller innhentes nytt samtykke, 
eller annen type godkjenning (dispensasjon fra 
taushetsplikten).
Informasjon fra Tromsøundersøkelsen kan også 
bli sammenstilt med registre ved Statistisk sen-
tralbyrå, for eksempel om miljø, befolkning, utdan-
ning, inntekt, offentlige ytelser, yrkesdeltakelse og 
andre forhold som kan ha betydning for helsa. 
Slike sammenstillinger krever noen ganger 
forhåndsgodkjenning av offentlige instanser, 
for eksempel Regional komité for medisinsk for-
skningsetikk, Datatilsynet eller NAV. 
Bruk av innsamlede data i framtiden
Data fra Tromsøundersøkelsen vil kun bli brukt til 
forskning og vil ikke kunne brukes til andre for-
mål. 
Opplysninger og prøver som du gir, blir oppbevart 
på ubestemt tid til bruk i forskning til formål som 
nevnt i denne brosjyren. I noen tilfeller kan det bli 
aktuelt å gjøre analyser av blodprøver ved forsk-
ningsinstitusjoner i utlandet. Hvis dette gjøres, vil 
det skje i en slik form at våre utenlandske sam- 
arbeidspartnere ikke kan knytte prøvene opp mot 
deg som person.
Hva som er aktuelle problemstillinger i medisinsk 
forskning forandrer seg hele tiden. I framtiden kan 
data bli brukt i forskningsprosjekter som i dag 
ikke er planlagt, forutsatt at det er i samsvar med 
gjeldende lover og forskrifter. For alle slike nye 
prosjekter kreves det at prosjektet er godkjent av 
Regional komité for medisinsk forskningsetikk og 
Datatilsynet. 
Tromsøundersøkelsen informerer om nye forsk-
ningsprosjekter på:  http://www.tromso6.no 
Her kan du også lese om forskningsresultatene 
fra Tromsøundersøkelsen. Forskningsresultater vil 
ellers bli publisert i internasjonale og nasjonale 
tidsskrifter, på faglige konferanser og møter. Det 
vil ikke være mulig å identifisere enkeltpersoner 
når forskningsresultatene offentliggjøres. 
Samtykke 
Hvis du vil delta i den sjette Tromsøundersøkelsen, 
må du gi skriftlig samtykke til dette. Personalet på 
Tromsøundersøkelsen vil kunne gi mer informa-
sjon om undersøkelsen, og kan svare deg dersom 
du har spørsmål i forbindelse med samtykket.
Det er viktig å vite at selv om du sier ja til dette nå, 
kan du senere ombestemme deg. Du kan når som 
helst etter undersøkelsen trekke ditt samtykke til-
bake. Allerede innsamlede data blir lagret videre, 
men kan ikke lenger knyttes til deg som person, og 
dine data vil ikke bli brukt i nye forskningsprosjek-
ter. Du kan be om at blodprøven din blir ødelagt. 
Hvis du vil trekke tilbake ditt samtykke, henvend 
deg til:
Tromsøundersøkelsen, Inst. for samfunnsmedisin
Universitetet i Tromsø
9037 Tromsø
telefon: 77 64 48 16
telefaks: 77 64 48 31
e-post: tromsous@ism.uit.no
internett: www.tromso6.no
Hvis vi i framtiden ønsker å forske på nye spørsmål 
som ikke er beskrevet i denne brosjyren, kan det 
bli nødvendig å be deg om et nytt samtykke.
Vil du delta?
Følgende tekst er en kopi av dokumentet du blir bedt om å signere når du møter fram til undersøkelsen:
Samtykke til bruk av helseopplysninger i forskning - den 6. Tromsøundersøkelsen
I brosjyren jeg har fått tilsendt, har jeg lest om undersøkelsens innhold og formål, og jeg har hatt 
mulighet til å stille spørsmål. Jeg samtykker herved i å delta i undersøkelsen [dato/signatur].
Tromsøundersøkelsen
Institutt for samfunnsmedisin, Universitetet i Tromsø
9037 TROMSØ
telefon: 77 64 48 16
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c Verken god eller dårlig
c Dårlig 
c Meget dårlig
2 Hvordan synes du at helsen din er sammenlignet 






3 Har du eller har du hatt? Ja Nei
Alder første 
gang
Hjerteinfarkt ............................................................... c c
Angina pectoris (hjertekrampe) ....................... c c
Hjerneslag/hjerneblødning ........................... c c
Hjerteflimmer (atrieflimmer) .............................. c c
Høyt blodtrykk ......................................................... c c
Beinskjørhet (osteoporose) .................................. c c
Astma ............................................................................... c c
Kronisk bronkitt/emfysem/KOLS ........... c c
Diabetes ......................................................................... c c
Psykiske plager (som du har søkt hjelp for) ....... c c
Lavt stoffskifte .......................................................... c c
Nyresykdom, unntatt urinveisinfeksjon... c c
Migrene .......................................................................... c c
4 Har du langvarige eller stadig tilbakevendende 
smerter som har vart i 3 måneder eller mer?
c Ja c Nei
5 Hvor ofte har du vært plaget av søvnløshet de siste 
12 måneder? 
c Aldri, eller noen få ganger
c 1-3 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn 1 gang i uken
6 Under finner du en liste over ulike problemer.  
Har du opplevd noe av dette den siste uken  









Plutselig frykt uten grunn ....... c c c c
Føler deg redd eller  
engstelig ................................................ c c c c
Matthet eller svimmelhet ...... c c c c
Føler deg anspent eller 
oppjaget ................................................ c c c c
Lett for å klandre deg selv .... c c c c
Søvnproblemer ................................ c c c c
Nedtrykt, tungsindig .................. c c c c
Følelse av å være unyttig, 
lite verd .................................................. c c c c
Følelse av at alt er et slit ......... c c c c
Følelse av håpløshet  
mht. framtida ................................... c c c c
7 Har du i løpet av de siste 12 måneder vært hos:  
Hvis JA; Hvor mange ganger?
Ja Nei Ant ggr
Fastlege/allmennlege ......................................... c c
Psykiater/psykolog ............................................... c c
Legespesialist utenfor sykehus 
(utenom fastlege/allmennlege/psykiater) ........... c c
Fysioterapeut ............................................................. c c
Kiropraktor ................................................................... c c
Annen behandler
(homøopat, akupunktør, fotsoneterapeut, natur-
medisiner, håndspålegger, healer, synsk el.l) ..... c c
Tannlege/tannpleier ............................................ c c
Skjemaet skal leses optisk. Vennligst bruk blå eller sort 
penn. Du kan ikke bruke komma, bruk blokkbokstaver.
2007 – 2008 Konfidensielt
9 Har du gjennomgått noen form for operasjon i løpet 
av de siste 3 årene?
c Ja c Nei
8 Har du i løpet av de siste 12 måneder vært på sykehus? 
Ja Nei Ant ggr
Innlagt på sykehus ................................................ c c
Konsultasjon ved sykehus uten innleggelse;
Ved psykiatrisk poliklinikk .................. c c
Ved annen sykehuspoliklinikk ........ c c
BRUK AV HELSETJENESTER
HELSE OG SYKDOMMER
19 Hva er din hovedaktivitet? (Sett ett kryss)
c Yrkesaktiv heltid c Hjemmeværende
c Yrkesaktiv deltid c Pensjonist/trygdet
c Arbeidsledig c Student/militærtjeneste
10 Bruker du, eller har du brukt, noen av følgende 






Medisin mot høyt blodtrykk ... c c c
Kolesterolsenkende medisin .... c c c
Medisin mot hjertesykdom .... c c c
Vanndrivende medisin ................ c c c
Medisin mot beinskjørhet 
(osteoporose) ............................................ c c c
Insulin ........................................................ c c c
Diabetesmedisin (tabletter) ........ c c c
Stoffskiftemedisinene  
Thyroxin/levaxin ............................. c c c
11 Hvor ofte har du i løpet av de siste 4 ukene brukt 











på resept ............... c c c c
Smertestillende 
reseptfrie ............... c c c c
Sovemidler .......... c c c c
Beroligende  
medisiner .............. c c c c
Medisin mot 
depresjon .............. c c c c
12 skriv ned alle medisiner – både de med og uten 
resept – som du har brukt regelmessig i siste 4 ukers 
periode. (Ikke regn med vitaminer, mineraler, urter, 
naturmedisin, andre kosttilskudd etc.)
Ved fRAMMØte vil du bli spurt om du har brukt 
antibiotika eller smertestillende medisiner de siste  
24 timene. Om du har det, vil vi be om at du oppgir 
preparat, styrke, dose og tidspunkt
13 Hvem bor du sammen med? (Sett kryss for hvert 
spørsmål og angi antall) 
Ja Nei Antall
Ektefelle/samboer ............................................. c c
Andre personer over 18 år ........................ c c
Personer under 18 år ...................................... c c
14 Kryss av for de slektninger som har eller har hatt
Foreldre Barn Søsken
Hjerteinfarkt .............................................. c c c
Hjerteinfarkt før fylte 60 år ......... c c c
Angina pectoris (hjertekrampe) ...... c c c
Hjerneslag/hjerneblødning .......... c c c
Beinskjørhet (osteoporose)  ................ c c c
Magesår/tolvfingertarmsår .......... c c c
Astma .............................................................. c c c
Diabetes ........................................................ c c c
Demens .......................................................... c c c
Psykiske plager ........................................ c c c
Rusproblemer ........................................... c c c
15 Har du nok venner som kan gi deg hjelp  
når du trenger det?
c Ja c Nei
16 Har du nok venner som du kan snakke fortrolig med?
c Ja c Nei
17 Hvor ofte tar du vanligvis del i foreningsvirksomhet 
som for eksempel syklubb, idrettslag, politiske lag, 
religiøse eller andre foreninger?
c Aldri, eller noen få ganger i året
c 1-2 ganger i måneden
c Omtrent 1 gang i uken
c Mer enn en gang i uken
ARBEID, TRYGD OG INNTEKT
18 Hva er din høyeste fullførte utdanning?  
(Sett ett kryss)
c Grunnskole, framhaldsskole eller folkehøyskole
c Yrkesfaglig videregående, yrkesskole eller realskole 
c Allmennfaglig videregående skole eller gymnas
c Høyskole eller universitet, mindre enn 4 år
c Høyskole eller universitet, 4 år eller mer
FAMILIE OG VENNERBRUK AV MEDISINER
Får du ikke plass til alle medisiner, bruk eget ark.
25 Hvor ofte driver du mosjon? (Med mosjon mener vi 
at du f.eks går en tur, går på ski, svømmer eller driver  
trening/idrett)
c Aldri
c Sjeldnere enn en gang i uken
c En gang i uken
c 2-3 ganger i uken
c omtrent hver dag
36 Hvor mange år til sammen har du røykt daglig?
Antall år
35 Hvor gammel var du da du begynte å røyke daglig?
Antall år
22 Arbeider du utendørs minst 25 % av tiden, eller i 
lokaler med lav temperatur, som for eksempel  
lager-/industrihaller?
c Ja c Nei
23 Hvis du er i lønnet eller ulønnet arbeid, hvordan vil 
du beskrive arbeidet ditt?
c For det meste stillesittende arbeid
(f.eks. skrivebordsarbeid, montering)
c Arbeid som krever at du går mye
(f.eks ekspeditørarbeid, lett industriarbeid, undervisning)
c Arbeid der du går og løfter mye
(f.eks postbud, pleier, bygningsarbeider)
c Tungt kroppsarbeid
24 Angi bevegelse og kroppslig anstrengelse i din  
fritid. Hvis aktiviteten varierer meget f eks mellom 
sommer og vinter, så ta et gjennomsnitt. spørsmålet 
gjelder bare det siste året. (Sett kryss i den ruta som 
passer best)
c Leser, ser på fjernsyn eller annen stillesittende  
beskjeftigelse
c Spaserer, sykler eller beveger deg på annen måte 
minst 4 timer i uken (her skal du også regne med gang 
eller sykling til arbeidsstedet, søndagsturer med mer)
c Driver mosjonsidrett, tyngre hagearbeid, snømåking 
e.l. (merk at aktiviteten skal vare minst 4 timer i uka)
c Trener hardt eller driver konkurranseidrett  
regelmessig og flere ganger i uka
26  Hvor hardt mosjonerer du da i gjennomsnitt?
c Tar det rolig uten å bli andpusten eller svett.
c Tar det så hardt at jeg blir andpusten og svett
c Tar meg nesten helt ut
29 Hvor mange enheter alkohol (en øl, et glass vin, eller 
en drink) tar du vanligvis når du drikker?
c 1-2 c 5-6 c 10 eller flere
c 3-4 c 7-9
32 Har du røykt/røyker du daglig?
c Ja, nå c Ja, tidligere c Aldri
27 Hvor lenge holder du på hver gang i gjennomsnitt ?
c Mindre enn 15 minutter c 30 minutter – 1 time
c 15-29 minutter c Mer enn 1 time
30 Hvor ofte drikker du 6 eller flere enheter alkohol ved 
en anledning?
c aldri
c sjeldnere enn månedlig
c månedlig
c ukentlig
c daglig eller nesten daglig
28 Hvor ofte drikker du alkohol? 
c Aldri
c Månedlig eller sjeldnere
c 2-4 ganger hver måned
c 2-3 ganger pr. uke
c 4 eller flere ganger pr.uke
21 Hvor høy var husholdningens samlede bruttoinntekt 
siste år? Ta med alle inntekter fra arbeid, trygder, 
sosialhjelp og lignende.
c Under 125 000 kr c 401 000-550 000 kr
c 125 000-200 000 kr c 551 000-700 000 kr
c 201 000-300 000 kr c 701 000 -850 000 kr 
c 301 000-400 000 kr c Over 850 000 kr
34 Hvis du røyker daglig nå eller har røykt tidligere: 
Hvor mange sigaretter røyker eller røykte du vanlig-
vis daglig?
Antall sigaretter
33 Hvis du har røykt daglig tidligere, hvor lenge er det 
siden du sluttet?
Antall år 
31 Røyker du av og til, men ikke daglig?
c Ja c Nei
20 Mottar du noen av følgende ytelser?
c Alderstrygd, førtidspensjon (AFP) eller etterlattepensjon




c Dagpenger under arbeidsledighet
c Overgangstønad
c Sosialhjelp/-stønad 
37 Bruker du, eller har du brukt, snus eller skrå?
c Nei, aldri c Ja, av og til
c Ja, men jeg har sluttet c Ja, daglig
FYSISK AKTIVITET
ALKOHOL OG TOBAKK
48 Hvis du har født, fyll ut for hvert barn: fødselsår og 
vekt samt hvor mange måneder du ammet.  
(Angi så godt som du kan)









39 Hvor mange enheter frukt og grønnsaker spiser du i 
gjennomsnitt per dag? (Med enhet menes f.eks. en 
frukt, glass juice, potet, porsjon grønnsaker)
Antall enheter
38 spiser du vanligvis frokost hver dag?
c Ja c Nei
40 Hvor mange ganger i uken spiser du varm middag? 
Antall
42 Hvor mye drikker du vanligvis av følgende?  















yoghurt .......................... c c c c c
Fruktjuice ...................... c c c c c
Brus/leskedrikker 
med sukker ................. c c c c c
44 Hvor ofte spiser du vanligvis fiskelever? 
(For eksempel i mølje)
c Sjelden/aldri c 1-3 g i året c 4-6 g i året































45 Bruker du følgende kosttilskudd?
Daglig Iblant Nei
Tran, trankapsler ..................................................... c c c
Omega 3 kapsler (fiskeolje,selolje) ............ c c c
Kalktabletter ............................................................ c c c
47 Hvor mange barn har du født?
Antall
49 Har du i forbindelse med svangerskap hatt for høyt  
blodtrykk?
c Ja c Nei
52 Hvis Ja, i hvilket svangerskap?
c Første c Senere
53 Ble noen av disse barna født mer enn en måned for 
tidlig (før termin) pga. svangerskapsforgiftning?
c Ja c Nei
55 Hvor gammel var du da du fikk menstruasjon  
første gang?
Antall år
51 Har du i forbindelse med svangerskap hatt protein  
(eggehvite) i urinen?
c Ja c Nei
50 Hvis Ja, i hvilket svangerskap? 
c Første c Senere
54 Hvis Ja, hvilke(t) barn
Barn 1 Barn 2 Barn 3 Barn 4 Barn 5 Barn 6
c c c c c c
43 Hvor mange kopper kaffe og te drikker du daglig? 






56 Bruker du for tiden reseptpliktige legemidler som 
påvirker menstruasjonen?
P-pille, hormonspiral eller lignende .......c Ja c Nei
Hormonpreparat for overgangs-
alderen .............................................................................c Ja c Nei
46 er du gravid nå?
c Ja c Nei c Usikker
Ved fRAMMØte vil du få utfyllende spørsmål om 
menstruasjon og eventuell bruk av hormoner. Skriv 
gjerne ned på et papir navn på hormonpreparater 
du har brukt, og ta det med deg. Du vil også bli 
spurt om din menstruasjon har opphørt og even-
tuelt når og hvorfor.
41 Hvor ofte spiser du vanligvis disse matvarene?
(Sett ett kryss pr linje)










Poteter ........................................ c c c c c
Pasta/ris ..................................... c c c c c
Kjøtt (ikke kvernet) ................ c c c c c
Kvernet kjøtt  
(pølser, hamburger o.l) ........... c c c c c
Grønnsaker, frukt, bær .. c c c c c
Mager fisk ............................... c c c c c
Feit fisk ....................................... c c c c c
(f.eks.laks, ørret, makrell, sild, kveite,uer)
KOSTHOLD SPØRSMÅL TIL KVINNER
                  Appendix 3                                                                                                                                                                                          
                   
- en del av Tromsøundersøkelsen
SLIK FYLLER DU UT SKJEMAET:




Om du krysser feil, retter du ved å fylle boksen slik
Skriv tydelige tall  1 2 3 4 5 6 7 8 9 0
Riktig
Galt




1.6 For at du skal kunne vise oss hvor god eller 
dårlig din helsetilstand er, har vi laget en 
skala (nesten som et termometer), hvor den 
beste helsetilstanden du kan tenke deg er 
markert med 100 og den dårligste med 0. 
Vi ber om at du viser din helsetilstand ved 
å trekke ei linje fra boksen nedenfor til det 



















1. BESKRIVELSE AV DIN HELSETILSTAND
Vis hvilke utsagn som passer best på din 
helsetilstand i dag ved å sette ett kryss i en 
av rutene utenfor hver av de fem gruppene 
nedenfor:
1.03 Vanlige gjøremål (f.eks. arbeid, studier, 
husarbeid, familie- eller fritidsaktiviteter)
Jeg har ingen problemer med å utføre 
mine vanlige gjøremål
Jeg har litt problemer med å utføre mine 
vanlige gjøremål
Jeg er ute av stand til å utføre mine 
vanlige gjøremål
1.04 Smerte og ubehag
Jeg har verken smerte eller ubehag
Jeg har moderat smerte eller ubehag
Jeg har sterk smerte eller ubehag
1.01 Gange
Jeg har ingen problemer med å gå 
omkring
Jeg har litt problemer med å gå omkring
Jeg er sengeliggende
1.02 Personlig stell
Jeg har ingen problemer med personlig stell
Jeg har litt problemer med å vaske meg 
eller kle meg
Jeg er ute av stand til å vaske meg eller 
kle meg 
1.05 Angst og depresjon
Jeg er verken engstelig eller deprimert
Jeg er noe engstelig eller deprimert
Jeg er svært engstelig eller deprimert
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2.01 Hvor bodde du da du fylte 1 år?
I Tromsø (med dagens kommunegrenser)
I Troms, men ikke i Tromsø 
I Finnmark fylke
I Nordland fylke
Annet sted i Norge
I utlandet
2. OPPVEKST OG TILHØRIGHET




2.02 Hvordan var de økonomiske forhold i 





2.07 Hva var/er den høyeste fullførte utdanning til dine foreldre og din ektefelle/samboer? 




Grunnskole 7-10 år, framhaldsskole eller folkehøyskole ...........
Yrkesfaglig videregående, yrkesskole eller realskole  ....................
Allmennfaglig videregående skole eller gymnas .................................
Høyskole eller universitet (mindre enn 4 år) ............................................
Høyskole eller universitet (4 år eller mer) ...................................................
2.06 Lever din mor?
Ja Nei
Hvis NEI: hennes alder ved død .........
Lever din far?
Ja Nei
Hvis NEI: hans alder ved død...............
2.04 Hva regner du deg selv som? (Kryss av for 










3.03 Jeg opplever at yrket mitt har følgende sosiale status i samfunnet: (dersom du ikke er i arbeid nå, 






3.01 Nedenfor står tre utsagn om tilfredshet med livet som et hele. Deretter står to utsagn om syn på din 
egen helse. Vis hvor enig eller uenig du er i hver av påstandene ved å sette et kryss i rubrikken for 




enig 1 2 3 4 5 6 7
På de fl este måter er livet mitt nær idealet mitt ..............
Mine livsforhold er utmerkede ............................................................
Jeg er tilfreds med livet mitt ...................................................................
Jeg ser lyst på min framtidige helse ...............................................
Ved å leve sunt kan jeg forhindre alvorlige 
sykdommer .................................................................................................................
3.02 Nedenfor står fi re utsagn om syn på forhold ved din nåværende jobb, eller hvis du ikke er i 




enigArbeidet mitt er for belastende, fysisk eller 
følelsesmessig ..........................................................................................................
1 2 3 4 5 6 7
Jeg har tilstrekkelig innfl ytelse på når og hvordan 
arbeidet mitt skal utføres ...........................................................................
Jeg blir mobbet eller trakassert på 
arbeidsplassen min ............................................................................................
Jeg blir rettferdig behandlet på arbeidsplassen min ....
3. TRIVSEL OG LIVSFORHOLD








Blitt plaget psykisk, eller truet med vold  ................................
Blitt slått, sparket eller utsatt for annen type vold ........
Noen i nær familie har brukt rusmidler på en slik 
måte at dette har vært til bekymring for deg .....................
Dersom du har opplevd noen av disse forholdene, hvor mye plages du av dette nå?
Ingen plager Noen plager Store plager 
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4.01 Har du i løpet av den siste måneden følt deg 
syk eller hatt en skade?
Ja Nei
4. SYKDOMMER OG PLAGER
4.03 Blir du tungpustet i følgende situasjoner? 
(sett ett kryss for hvert spørsmål)
Ja Nei
Når du går hurtig på fl atmark eller 
svak oppoverbakke ....................................................
Når du spaserer i rolig tempo på 
fl atmark ...................................................................................
Når du vasker deg eller kler på deg ........
Når du er i hvile .............................................................
4.04 Hoster du omtrent daglig i perioder av året?
Ja Nei
Hvis JA: Er hosten vanligvis ledsaget av 
oppspytt?
Ja Nei
Har du hatt slik hoste så lenge som i en 3 
måneders periode i begge de to siste årene?
Ja Nei
4.02 Har du merket anfall med plutselig endring i 
pulsen eller hjerterytmen siste året?
Ja Nei
4.09 Nedenfor ber vi deg besvare noen spørsmål 
om din hukommelse: (sett ett kryss for hvert 
spørsmål)
Ja Nei
Synes du at din hukommelse har 
blitt dårligere? ..................................................................
Glemmer du ofte hvor du har lagt 
tingene dine? ....................................................................
Har du problemer med å fi nne 
vanlige ord i en samtale? ....................................
Har du fått problemer med daglige 
gjøremål som du mestret tidligere?.........
Har du vært undersøkt for 
sviktende hukommelse? .......................................
Hvis JA: har du i den samme perioden? 
(sett ett kryss for hver linje)
Ja Nei
Vært hos allmennlege/fastlege ....................
Vært hos spesialist.......................................................
Vært på legevakt ..........................................................
Vært innlagt i sykehus ............................................
Vært hos alternativ behandler 
(kiropraktor, homøopat eller lignende) ...........................
Hvis JA på minst ett av de fi re første spørs-
målene ovenfor: Er det et problem i hverdagen?
Ja Nei
4.05 Hvor ofte er du plaget av søvnløshet? 
(sett ett kryss)
Aldri, eller noen få ganger i året
1-3 ganger i måneden
Omtrent 1 gang i uka
Mer enn 1 gang i uka
Hvis du er plaget av søvnløshet månedlig 
eller oftere, når på året er du mest plaget? 





4.06 Har du i de siste par ukene hatt vansker 
med å sove?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
4.07 Har du de siste par ukene følt deg ulykkelig 
og nedtrykt (deprimert)?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
4.08 Har du i de siste par ukene følt deg ute av 
stand til å mestre dine vanskeligheter?
Ikke i det hele tatt
Ikke mer enn vanlig
Heller mer enn vanlig
Mye mer enn vanlig
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4.17 Hvis du har hatt smerter i eller ubehag fra 
magen siste året:
Ja Nei
Er disse lokalisert øverst i magen? ............
Har du hatt plagene så ofte som 1 dag 
i uka eller mer de siste 3 måneder? ........
Blir plagene bedre etter avføring? ............
Har plagene sammenheng med 
hyppigere eller sjeldnere avføring 
enn vanlig? ..........................................................................
Har plagene noen sammenheng med 
løsere eller fastere avføring enn vanlig? ...
Kommer plagene etter måltid? ....................
4.15 Har du opplevd ufrivillig barnløshet i mer 
enn 1 år?
Ja Nei
Hvis JA, skyldtes dette: Vet 
ikkeJa Nei
Forhold hos deg selv? ..............
Forhold hos partneren? ..........





4.19 Til kvinnen: Har du spontanabortert?
Ja Nei Vet ikke
Hvis JA, antall ganger ..............................
4.16 I hvilken grad har du hatt følgende plager i 






Vekslende treg mage 
og diare.......................................................
Oppblåsthet ..........................................
Smerter i magen .......................
4.20 Til mannen: Har din partner noen gang 
spontanabortert?
Ja Nei Vet ikke
Hvis JA, antall ganger ..............................
4.22 Har du fått stilt diagnosen Dermatitis 
Herpetiformis (DH)?
Ja Nei Vet ikke
4.21 Bruker du glutenfri diett?
Ja Nei Vet ikke
4.11 Har du vært plaget med smerter og/eller 
stivhet i muskler og ledd i løpet av de 









Øvre del av ryggen ....
Korsryggen ..........................
Hofter, ben, føtter .......
Andre steder ......................
4.10 Har du i løpet av det siste året vært plaget 
med smerter og/eller stivhet i muskler og 
ledd som har vart i minst 3 måneder sammen-









Øvre del av ryggen ....
Korsryggen ..........................
Hofter, ben, føtter .......
Andre steder ......................





4.18 Har du noen gang hatt: Alder 
siste gangJa Nei
Sår på magesekken .....................
Sår på tolvfi ngertarmen ......
Magesår-operasjon ..................4.13 Har du fått stilt diagnosen slitasjegikt av lege?
Ja Nei
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4.27 Hva slags hodepine er du plaget av?
Migrene Annen hodepine
4.28 Omtrent hvor mange dager per måned har 
du hodepine?
Mindre enn 1 dag
1-6 dager 
7-14 dager
Mer enn 14 dager
4.26 Har du vært plaget av hodepine det siste året?
Ja Nei
Hvis NEI, gå til del 5, kosthold
4.30 Hvor sterk er hodepinen vanligvis?
Mild (hemmer ikke aktivitet)
Moderat (hemmer aktivitet)
Sterk (forhindrer aktivitet)
4.31 Hvor lenge varer hodepinen vanligvis?
Mindre enn 4 timer
4 timer – 1 døgn
1-3 døgn
Mer enn 3 døgn
4.29 Er hodepinen vanligvis: 




Ensidig smerte (høyre eller venstre) ..................
4.33 Før eller under hodepinen, kan du da ha 
forbigående:
Ja Nei
Synsforstyrrelse? (takkede linjer, fl imring, 
tåkesyn, lysglimt) ...................................................................
Nummenhet i halve ansiktet eller i 
hånden? ...................................................................................
Forverring ved moderat fysisk aktivitet 
Kvalme og /eller oppkast .....................................
4.34 Angi hvor mange dager du har vært borte 
fra arbeid eller skole siste måned på grunn 
av hodepine: 
Antall dager ......................................................................
4.32 Dersom du er plaget av hodepine, når på året 





4.23 Har du fått stilt diagnosen cøliaki på 
bakgrunn av en vevsprøve fra tynntarmen 
tatt under en undersøkelse der du svelget 
en slange (gastroskopi)?
Ja Nei Vet ikke
4.24 Har du egne tenner? 
Ja Nei
4.25 Hvor mange amalgamfyllinger har du/har 
du hatt?
0 1-5 6-10 10+
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5. KOSTHOLD








3 g per uke
Ferskvannsfi sk (ikke oppdrett) .........................................................................
Saltvannsfi sk (ikke oppdrett) ..............................................................................
Oppdrettsfi sk (laks, røye, ørret) .......................................................................
Tunfi sk (fersk eller hermetisert) ..........................................................................
Fiskepålegg ......................................................................................................................
Skjell ........................................................................................................................................
Den brune innmaten i krabbe ...................................................................
Hvalkjøtt/sel/kobbekjøtt .................................................................................
Innmat fra rein eller elg .....................................................................................
Innmat fra rype ...........................................................................................................
5.02 Hvor mange ganger i året spiser du/spiste du vanligvis følgende? (antall ganger)
Som voksen I din barndom
Mølje (Antall ganger i året) .........................................................................................................................
Måsegg (Antall egg i året) ..........................................................................................................................
Reinsdyrkjøtt (Antall ganger i året) ....................................................................................................
Selvplukket sopp og bær (blåbær/tyttebær/multe) (Antall ganger i året) ........
5.03 Hvor mange ganger i måneden spiser du 
hermetiske matvarer (fra metallbokser)?
Antall ...........................................................................................
5.04 Bruker du vitaminer og/eller mineraltilskudd?
Ja, daglig Iblant Aldri


























3 g. per dag 
eller mer
5.06 Hvis du spiser sjokolade, hvor mye pleier du vanligvis å spise hver gang?
Tenk deg størrelsen på en Kvikk- Lunsj sjokolade, og oppgi hvor mye du spiser i forhold til den.





8.01 Hvor mange timer i uka driver du med 
følgende fritids- eller yrkesaktiviteter: 
Bilreparasjoner/lakkering, keramikkarbeid, 
maling/lakkering/løsemidler, frisør, glassmester, 
elektriker (Sett 0 om du ikke driver med slike 
fritids eller yrkesaktiviteter)
Antall timer per uke i gjennomsnitt .........
8.02 Bruker du hårfargemidler?
Ja Nei
Hvis JA, hvor mange ganger per år? ..
7.01 Har du ufrivillig gått ned i vekt siste  6 
måneder?
Ja Nei
Hvis JA: Hvor mange kilo? ....................
7.03 Er du fornøyd med vekta di nå?
Ja Nei
7.02 Anslå din vekt da du var 25 år gammel:
Antall hele kg ..............................................








6.02 Har du eller andre noen gang blitt skadet på grunn av at du har 
drukket? .................................................................................................................................................................
Har en slektning, venn, lege, eller annet helsepersonell vært 







6.01 Hvor ofte har du det siste året:
Aldri Månedlig Ukentlig
Ikke klart å stoppe og drikke alkohol når 
du først har begynt? ..............................................................
Ikke klart å gjøre det som normalt 
forventes av deg fordi du har drukket? ..........
Trengt en drink om morgenen for å få 
komme i gang etter en rangel? ....................................
Følt skyld eller anger etter at du har 
drukket? ...............................................................................................
Ikke klart å huske hva som skjedde kvelden 
før på grunn av at du hadde drukket? .............
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9.09 Alt i alt, har du opplevd at det er vanskelig 







9. BRUK AV HELSETJENESTER
9.01 Har du noen gang opplevd at sykdom er blitt 
mangelfullt undersøkt eller behandlet, og at 
dette har gitt alvorlige følger?
Ja, det har rammet meg selv 
Ja, det har rammet en nær pårørende 
(barn, foreldre, ektefelle/samboer)
Nei
Hvis JA, hvor mener du årsaken ligger? 





hos annet helsepersonell 
hos alternativ behandler
hos fl ere på grunn av svikt i rutiner og 
samarbeid
9.03 Har du noen gang klaget på behandling 
du har fått?
Har aldri vært aktuelt
Har vurdert å klage, men ikke gjort det
Har klaget muntlig
Har klaget skriftlig 
9.04 Hvor lenge har du hatt din nåværende 
fastlege/annen lege?
Mindre enn 6 måneder
6 til 12 måneder
12 til 24 måneder
Mer enn 2 år
9.02 Har du noen gang følt deg overtalt til å 
godta undersøkelse eller behandling som du 
selv ikke ønsket? 
Ja Nei
Hvis JA, mener du dette har hatt uheldige 
helsemessige følger?
Ja Nei
9.05 Ved siste legebesøk hos fastlegen, snakket 
legen(e) til deg slik at du forsto dem? Svar på 
en skala fra 0 til 10, hvor 0=de var vanskelige 
å forstå og 10=de var alltid enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
9.06 Hvordan vil du karakterisere behandlingen 
eller rådgivingen du fi kk siste gang du var 
hos lege? Svar på en skala fra 0 til 10,  hvor 
0= meget dårlig behandling og 10 = meget 
god behandling
0 1 2 3 4 5 6 7 8 9 10
9.07 Har du i løpet av de siste 12 måneder 
opplevd at det har vært vanskelig å bli 
henvist til spesielle undersøkelser (som 
røntgen eller liknende) eller til spesialist-
helsetjenesten (privatpraktiserende 





9.08 Har du i løpet av de siste 12 måneder 
opplevd at det er vanskelig å bli henvist til 






9.13 Har du i løpet av de siste 12 måneder brukt 
urtemedisin , naturmidler eller naturlegemidler?
Ja Nei
9.10 Har du i løpet av de siste 12 måneder vært til 
undersøkelse eller behandling i spesialist-
helsetjenesten?
Ja Nei
9.14 Har du i løpet av de siste 12 måneder brukt 
meditasjon, yoga, qi gong eller thai chi som 
egenbehandling?  
Ja Nei
9.12 Har du noen gang før 2002 gjennomgått 
en operasjon på sykehus eller spesialist-
klinikk?
Ja Nei
9.11 Hvordan vil du karakterisere behandlingen 
eller rådgivningen du fi kk siste gang du var 
hos spesialist? Svar på en skala fra 0 til 10, 
hvor 0=meget dårlig og 10=meget god
0 1 2 3 4 5 6 7 8 9 10
Hvis JA, snakket legen(e) til deg slik at du 
forstod dem? Svar på en skala fra 0 til 10, hvor 
0=de var vanskelige å forstå og 10=de var alltid 
enkle å forstå
0 1 2 3 4 5 6 7 8 9 10
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10. BRUK AV ANTIBIOTIKA
10.01 Har du brukt antibiotika i løpet av de siste 12 måneder? (all penicillinliknende medisin i form av 
tabletter, mikstur eller sprøyter)
Ja Nei Husker ikke
Hvis JA, hva fi kk du behandling mot? Har du tatt 
fl ere antibiotikakurer, sett ett kryss for hver kur. Kur 1 Kur 2 Kur 3 Kur 4 Kur 5 Kur 6
· Urinveisinfeksjon (blærebetennelse, blærekatarr) .....................
· Luftveisinfeksjon (øre-, bihule- hals- eller lungebetennelse, 
bronkitt).....................................................................................................................
· Annet .....................................................................................................................
Antall dagers antibiotika kur ...................................................................
Hvordan skaffet du deg antibiotikakuren? Har du tatt 
fl ere kurer, sett ett kryss for hver kur.
Etter resept fra lege/tannlege ....................................................................
Uten kontakt med lege/uten resept:
· Kjøp direkte fra apotek i utlandet .............................................
· Kjøp gjennom Internett ........................................................................
· Rest fra tidligere kur tilgjengelig hjemme ........................
· Fått av familie/venner ............................................................................
· Andre måter .......................................................................................................
10.02 Har du antibiotika hjemme?  
Ja Nei
10.03 Kan du tenke deg å bruke antibiotika uten å 
kontakte lege først?
Ja Nei
Hvis JA, er dette etter avtale med lege for 
å behandle kronisk eller hyppig tilbake-
vendende sykdom?
Ja Nei
Hvis Nei, hvordan skaffet du deg dette 
legemiddelet? (Flere kryss er mulig)
Kjøpt direkte fra apotek i utlandet ...................
Kjøpt over Internett ...........................................................
Rest fra tidligere kur .........................................................
Fått av familie/venner ....................................................
Andre måter ...............................................................................
Hvis JA, hvilke tilstander vil du i så fall 














Da går jeg til sengs klokken ........................................................................................................................................................
Jeg gjør meg klar til å sove klokken ...................................................................................................................................
Antall minutter jeg trenger på å sovne ..............................................................................................................................................
Jeg våkner klokken ................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning (støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..........................................................................................................................................
Da går jeg til sengs klokken ........................................................................................................................................................
Jeg gjør meg klar til å sove klokken ...................................................................................................................................
Antall minutter jeg trenger på å sovne ..............................................................................................................................................
Jeg våkner klokken ................................................................................................................................................................................
Ved hjelp av: Vekkeklokke annen ytre påvirkning ( støy, familie etc) av meg selv
Antall minutter jeg trenger på å stå opp ..........................................................................................................................................
11.02 Antall dager i løpet av uken hvor du ikke kan velge fritt når du vil sove (f.eks arbeidsdager)?
0 1 2 3 4 5 6 7
Vi vil stille deg noen spørsmål  som handler om dine søvnvaner. 
11.03 Antall dager i løpet av uken hvor du fritt kan velge når du vil sove (f.eks helger eller fridager)
0 1 2 3 4 5 6 7
11.01 Har du hatt skiftarbeid de tre siste månedene?
Ja Nei
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12.07 Har du tilbakevendende store kviser/
verkebyller som er ømme/smertefulle 
og som ofte tilheler med arr på følgende 








Hvis JA, hvor mange ganger i gjennomsnitt 
per år fi kk du antibiotika i den perioden du 
var mest plaget (sett ett kryss)
1-2 3-4 Mer enn 4 ganger
12.05 Har du ofte eller bestandig noen av 
følgende plager? (sett ett kryss for hver linje)
Ja Nei
Hevelse i ankler og legger, særlig 
om kvelden ........................................................................
Åreknuter ............................................................................
Eksem (rødt, kløende utslett) på 
leggene ..................................................................................
Smerter i beina når du går, men 
som forsvinner når du står stille ................
12.04 Har du eller har du noen gang hatt følgende 
hudlidelser? (sett ett kryss for hver linje)
Ja Nei
Psoriasis ...................................................................................
Atopisk eksem (barneeksem) .........................
Tilbakevendende håndeksem .........................
Tilbakevendende kviser over fl ere 
måneder ..................................................................................
Legg- eller fotsår som ikke ville gro i 
løpet av 3-4 uker ..........................................................
12. HUD OG HUDSYKDOMMER
Hvis JA på spørsmål om legg-og/eller fotsår, 
har du leggsår i dag?
Ja Nei
12.03 Har du noen gang fått antibiotikakur 
(penicillin og liknende medisin) på grunn 
av en hudlidelse, for eksempel betent 
eksem, kviser, leggsår som ikke vil gro, 
tilbakevendende verkebyll? 
Ja Nei
12.01 Hvor ofte dusjer eller bader du vanligvis? 
(sett ett kryss)
2 eller fl ere ganger daglig
1 gang daglig
4-6 ganger per uke
2-3 ganger per uke
1 gang per uke
sjeldnere enn 1 gang per uke
12.02 Hvor ofte vasker du vanligvis hendene med 





Mer enn 20 ganger
12.06 Har du noen gang fått følgende diagnoser 





Hvis JA, fi kk du da noen av følgende 





Større kirurgisk inngrep med 
fjerning av hud ..............................................................
Kirurgisk laserbehandling ..................................





De neste sidene med spørsmål skal ikke besvares av alle. Dersom du har svart ja på ett eller fl ere av 
spørsmålene under, ber vi deg om å gå videre til oppfølgingsspørsmål om emnet eller emnene du 
har svart ja på. De fi re første emnene er fra det første spørreskjemaet og det siste spørsmålet er fra 
dette skjemaet.
Vi har for enkelhetsskyld markert emnene med ulike farger slik at du lett skal fi nne frem til de spørs-
målene som gjelder for deg. 
Dersom du svarte JA på at du har: langvarige eller stadig tilbakevendende smerter som har vart i 3 
måneder eller mer, ber vi deg svare på spørsmålene på side 19 og 20. Margen er markert med grønn.
Dersom du svarte JA på at du har gjennomgått noen form for operasjon i løpet av de siste 3 årene, 
ber vi deg svare på spørsmålene på side 21 og 22. Margen er markert med lilla.
Dersom du svarte JA på at du arbeider utendørs minst 25% av tiden, eller i lokaler med lav 
temperatur, som for eksempel lager/industrihaller, ber vi deg svare på spørsmålene på side 23. 
Margen er markert med rød.
Dersom du svarte JA på at du har brukt reseptfrie smertestillende medisiner, ber vi deg svare på 
spørsmålene på side 24. Margen er markert med orange.
Dersom du svarte JA på at du har eller noen gang har hatt plager med hud (som psoriasis, atopisk 
eksem, legg- eller fotsår som ikke vil gro, tilbakevendende håndeksem, kviser eller verkebyll), ber vi 
deg svare på spørsmålene på side 25. Margen er markert med gul.
Har du svart NEI på disse fem spørsmålene, er du ferdig med besvarelsen din. Spørreskjemaet 
returneres i svarkonvolutten du fi kk utlevert på undersøkelsen. Portoen er allerede betalt. 
Skulle du ønske å gi oss en skriftlig tilbakemelding om enten spørreskjema eller Tromsøundersøkelsen 
generelt, er du hjertelig velkommen til det på side 26.
Har du noen spørsmål, kan du ta kontakt med oss på telefon eller på e-post. Du fi nner kontakt-
informasjon på baksiden av skjemaet. TUSEN TAKK for at du tok deg tid til undersøkelsen og 
til å svare på spørsmålene fra oss.
INFORMASJON TIL OPPFØLGINGSSPØRSMÅL
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13.01 Hvor lenge har du hatt disse smertene?
Antall år ............. måneder ............










13.02 Hvor ofte har du vanligvis disse smertene?
Hver dag En eller fl ere ganger i måneden
En eller fl ere ganger i uken Sjeldnere enn 1 gang i måneden
13.05 Hvilke former for behandling har du fått for smertene? (Kryss av for alle typer 
smertebehandling du har mottatt)
Ingen behandling Smerteskole/avspenning/psykoterapi
Smertestillende medisiner Akupunktur
Fysioterapi/kiropraktikk Alternativ behandling (homøopati, healing, 
aromaterapi, m.m.)Behandling ved smerteklinikk
Operasjon Annen behandling
Du svarte i det første spørreskjemaet at du har langvarige eller stadig tilbakevendende smerter som 
har vart i 3 måneder eller mer. Her ber vi deg beskrive de smertene litt nærmere.
13. OPPFØLGINGSSPØRSMÅL OM SMERTE 
13.04 Hva mener du er årsaken til smertene? (Kryss av for alle kjente årsaker)
Ulykke/akutt skade Fibromyalgi
Langvarig belastning Angina pectoris (hjertekrampe)





Leddgikt Annen årsak (beskriv under)




13.06 På en skala fra 0 til 10, der 0 tilsvarer ingen smerte og 10 tilsvarer den verst tenkelige smerten 




å få soveI hvor stor grad påvirker smertene 
søvnen din? ...................................................................





I hvor stor grad hindrer smertene 
deg i å utføre vanlige aktiviteter 
hjemme og i arbeid? ............................................





smerteHvor sterke er smertene når de er på 
sitt sterkeste? ..................................................................





smerteHvor sterke vil du si at smertene 
vanligvis er? ...................................................................
0 1 2 3 4 5 6 7 8 9 10
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14. OPPFØLGINGSSPØRSMÅL OM OPERASJON
I det første spørreskjemaet svarte du at du har gjennomgått en operasjon i løpet av de siste 3 
årene.
Nedenfor ber vi deg beskrive operasjonen. Dersom du har gjennomgått fl ere operasjoner i løpet 
av de siste 3 årene gjelder disse spørsmålene den siste operasjonen du gjennomgikk.
14.02 Hvor i kroppen ble du operert? (Dersom du 
samtidig ble operert fl ere steder i kroppen, 




























14.03 Bakgrunn for operasjonen:
Akutt sykdom/skade ........................................................
Planlagt ikke-kosmetisk operasjon ...................
Planlagt kosmetisk operasjon .................................
14.04 Hvor ble du operert?
Sykehuset i Tromsø ................................................................
Sykehuset i Harstad ...........................................................
Annet offentlig sykehus ................................................
Privat klinikk ...............................................................................
14.01 Hvor mange operasjoner har du totalt gjennomgått de siste 3 årene?
Antall ..............................................................................................................................................................................
14.05 Hvor lenge er det siden du gjennomgikk 
operasjonen?
Antall år ........... måneder ..........
14.06 Har du nedsatt følsomhet i et område nær 
operasjonsarret?
Ja Nei
14.07 Er du overfølsom for berøring, varme eller 
kulde i et område nær operasjonsarret? 
Ja Nei
14.08 Kan lett berøring av klær, dusj og lignende 
fremkalle ubehag/smerte? 
Ja Nei
14.09 Hvis du hadde smerter på operasjonsstedet 










smerteHvor sterke smerter hadde du fra 
operasjonsstedet før operasjonen ........





smerteHvor sterke smerter har du vanligvis 
fra operasjonsstedet nå ....................................






Hvor sterke smerter har du nå fra 
operasjonsstedet når smertene er 
på det sterkeste .........................................................
0 1 2 3 4 5 6 7 8 9 10
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15.06 Har du i løpet av de siste 12 måneder vært 
involvert i ulykke som krevde medisinsk 




15.02 Hvor lenge har du vært utsatt for kalde 
omgivelser under 0°C sist vinter?
Fritid/hobby (timer/uke) ...........................................
Arbeid (timer/uke) ...........................................................
Utendørs, godt kledd (timer/uke) ..................
Utendørs, tynnkledd (timer/uke) ....................
Innendørs, uten oppvarming (timer/uke) ...
I kalde omgivelser, med våte klær 
(timer/uke) ................................................................................
Kontakt med kalde gjenstander/
verktøy (timer/uke) .........................................................
15. OPPFØLGINGSSPØRSMÅL OM ARBEID I KALDT KLIMA
I det første spørreskjemaet svarte du ja på at du arbeidet i kaldt klima. Her er noen oppfølgings-
spørsmål vi håper du vil svare på.




15.05 Har du opplevd kløe og/eller utslett i 
forbindelse med kulde?
Ja Nei
15.07 Opplever du noen av følgende symptomer 
mens du oppholder deg i kalde omgivelser? 
I så fall, ved hvilken temperatur oppstår 
symptomene?
Ja Nei Under °C
Pusteproblemer ...............................
Pipende pust .......................................
Slim fra lungene ..............................
Brystsmerter ........................................
Forstyrrelse i hjerterytmen ..





Hvite fi ngre (kortvarig/
forbigående) ..............................................
Blå, blå-røde fi ngre 
(kortvarig/forbigående) .....................






Kontroll av bevegelse (for eksempel skjelving) .........................................................
Tungt fysisk arbeid..........................................................................................................................
Langvarig fysisk arbeid ..............................................................................................................
15.03 Hvilken omgivelsestemperatur 




Utføre andre aktiviteter utendørs ...
15.04 Har du hatt forfrysninger siste 12 måneder, 
med blemmer, sår eller skader i huden?
Ja Nei
Hvis JA, hvor mange ganger? .............
24
16. BRUK AV RESEPTFRIE SMERTESTILLENDE LEGEMIDLER
Paracetamol: (Pamol, Panodil, Paracet, 
Paracetamol, Pinex)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, stikkpiller) ......................................
16.01 Hvilke typer reseptfrie smertestillende 
legemidler har du brukt?
Ibuprofen: (Ibumetin, Ibuprofen, Ibuprox, Ibux)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter, stikkpiller) ......................................
Acetylsalisylsyre: (Aspirin,Dispril, Globoid)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 




Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter) ................................................................






16.02 Mot hvilke plager bruker du reseptfrie 








Fenazon med koffein: (Antineuralgica ,Fanalgin 
Fenazon-koffein, Fenazon-koffein sterke)
Ikke brukt
Sjeldnere enn hver uke
Hver uke, men ikke daglig
Daglig
Hvor mye tar du vanligvis daglig 
når du bruker midlene? 
(Antall tabletter) ................................................................
16.05 Kombinerer du behandlingen med bruk av 
reseptbelagte smertestillende midler?
Ja Nei
16.03 Mener du å ha opplevd bivirkninger av noen 






Fenazon med koffein .............................................
I det første spørreskjemaet svarte du at du hadde brukt reseptfrie smertestillende legemidler de 
siste 4 ukene. Her er noen oppfølgingsspørsmål vi håper du vil svare på.
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17. OPPFØLGINGSSPØRSMÅL OM HUDSYKDOMMER
På side 15 i dette spørreskjemaet svarte du at du har eller har hatt en hudsykdom. Her er noen 
oppfølgingsspørsmål vi håper du vil svare på.
17.08 Hvor gammel var du da du fi kk verkebyller 
første gang?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år Over 50 år
17.07 Hvor mange utbrudd av verkebyller har du 
vanligvis i løpet av ett år? (sett ett kryss) 
0-1 4-6
2-3 Mer enn 6
17.09 Dersom du ikke lenger har verkebyller, hvor 
gammel var du da plagene forsvant?
0-12 år 26-35 år
13-19 år 36-50 år  
20-25 år Over 50 år
17.06 Her er en liste over faktorer som kan tenkes 
å utløse eller forverre verkebyller, kryss av 







Svar på en skala fra 0 til 10, der 0 tilsvarer ingen plager og 10 tilsvarer 




17.01 Psoriasis Ingen 
plager· Hvor mye plaget er du av din 
psoriasis i dag? .........................................................
0 1 2 3 4 5 6 7 8 9 10
· Hvor mye plaget er du av din 
psoriasis når den er som verst? .............
17.02 Atopisk eksem
· Hvor mye plaget er du av ditt 
atopiske eksem i dag? ..........................................
· Hvor mye plaget er du av ditt 
atopiske eksem når det er 
som verst? .....................................................................
17.03 Håndeksem
· Hvor mye plaget er du av ditt 
håndeksem i dag? ...................................................
· Hvor mye plaget er du av ditt 
håndeksem når det er som verst? ......
17.04 Kviser
· Hvor mye plaget er du av dine 
kviser i dag? ........................................................................
· Hvor mye plaget er du av dine 
kviser når de er som verst? ........................
17.05 Verkebyller
· Hvor mye plaget er du av dine 
verkebyller i dag? ..................................................
· Hvor mye plaget er du av dine 
verkebyller når de er som verst?..........
Skulle du ønske å gi oss en skriftlig tilbakemelding om enten spørreskjema eller 
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NHANES’ record of important accomplishments is
made possible by the thousands of Americans who
have participated.
• Past surveys have provided data to create the
growth charts used nationally by pediatricians
to evaluate children’s growth.  The charts have
been adapted and adopted worldwide as a
reference standard—and have recently been
updated using the latest NHANES figures.
• Blood lead data were instrumental in develop-
ing policy to eliminate lead from gasoline and
solder in food and soft drink cans.  Recent
survey data indicate the policy has been even
more effective than originally envisioned,
with a decline in elevated blood lead levels of
more than 70% since the 1970’s.
• Overweight prevalence figures have led to the
proliferation of programs emphasizing diet
and exercise, stimulated additional research,
and provided a means to track trends in obesity.
 • Data have continued to indicate that undiag-
nosed diabetes is a significant problem in the
United States.  Efforts by Government and
private agencies to increase public awareness,
especially among minority populations, have
been intensified.
These are just a few examples of what survey
findings have meant.  The current program
promises continuing contributions and some new
initiatives.
 • Information collected in this survey will help
the Food and Drug Administration decide if
there is a need to change vitamin and mineral
fortification regulations for the Nation’s food
supply.
 • The national programs to reduce hypertension
and cholesterol levels continue to depend on
NHANES data to steer education and preven-
tion programs toward those at risk and to
measure success in curtailing risk factors
associated with heart disease, the Nation’s
number one cause of death.
 • New measures of physical fitness will
further our understanding of its role in
health and enhance the analysis of
relationships between exercise and obesity
and disease.
Because NHANES is now an ongoing pro-
gram, the information collected will contrib-
ute to annual estimates in some topic areas
included in the survey.  For small population
groups and less prevalent conditions and
diseases, data must be accumulated over
several years to provide adequate estimates.
The new continuous design also allows
increased flexibility in survey content.
Results of NHANES will benefit people in
the United States in important ways.  Facts
about the distribution of health problems and
risk factors in the population give researchers
important clues to the causes of disease.
Information collected from the current survey
will be compared with information collected
in previous surveys.  This will allow health
planners to detect the extent various health
problems and risk factors have changed in the
U.S. population over time.  By identifying the
health care needs of the population, govern-
ment agencies and private sector organiza-
tions can establish policies and plan research,
education, and health promotion programs
that will help improve present health status
and prevent future health problems.
For more information about the National Center for Health Statistics contact:
Data Dissemination Branch
National Center for Health Statistics
Room 1064, Metro III Bldg.
6525 Belcrest Road
Hyattsville, Maryland 20782-2003
Telephone: (301) 458-INFO (4636)
E-mail: nchsquery@cdc.gov
Internet: www.cdc.gov/nchs
For more information about the National Health and Nutrition Examination Survey
you may visit the NHANES web site at: www.cdc.gov/nhanes
01-0516 (8/01)
National Health and 
Nutrition Examination Survey 
Overview 
DEPARTMENT OF HEALTH AND HUMAN SERVICES 
Centers for Disease Control and Prevention 
National Center for Health Statistics 
The sample for the survey is selected to represent
the U.S. population of all ages.  Special emphasis
in the current NHANES will be on adolescent
health and the health of older Americans.  To
produce reliable statistics for these groups, ado-
lescents 15–19 and persons 60 and older are over-
sampled for the survey. African Americans and
Mexican Americans are also over-sampled to
enable accurate estimates for these groups.
Several important areas in adolescent health,
including nutrition and fitness and other aspects
of growth and development, will be addressed.
Since the United States has experienced dramatic
growth in the number of older people during this
century, the aging population has major implica-
tions for health care needs, public policy, and
research priorities.  NCHS is working with public
health agencies to increase the knowledge of the
health status of older Americans.  NHANES has a
primary role in this endeavor.
In the examination, all participants visit the physi-
cian who takes their pulse or blood pressure.  Di-
etary interviews and body measurements are
included for everyone.  All but the very young have
a blood sample taken and see the dentist.  Depend-
ing upon the age of the participant, the rest of the
examination includes tests and procedures to assess
the various aspects of health listed above.  Usually,
the older the individual, the more extensive the
examination.  Some persons who are unable to
come to the examination center may be given a less
extensive examination in their homes.
Survey Operations
Health interviews are conducted in respondents’
homes.  Examinations are performed in spe-
cially-designed and equipped mobile examina-
tion centers, which travel to survey locations
throughout the country. The survey team con-
sists of a physician, dentist, medical and health
technicians, dietary and health interviewers.  A
large staff of trained bilingual interviewers
conducts the household interviews.
An advanced computer system using high-end
servers, desktop PCs, and wide-area networking
collects and processes all of the NHANES data,
nearly eliminating the need for paper forms and
manual coding operations.  This system allows
interviewers to use notebook computers with
electronic pens.  The staff at the mobile exam
center can automatically transmit data into data
bases through such devices as digital scales and
stadiometers.  Touch-sensitive computer screens
let respondents enter their own responses to
certain sensitive questions in complete privacy.
Survey information is available to NCHS staff
within 24 hours of collection, which will en-
hance the capability of collecting quality data
and will increase the speed with which results
are released to the public.
In each location, local health and government
officials are notified of the upcoming survey.
Households in the survey receive a letter from
the NCHS Director to introduce the survey.
Local media may feature stories about the
survey.
NHANES is designed to facilitate and encourage
participation.  Transportation is provided to and
from the examination center and participants
receive compensation.  A report of medical and
dental findings is given to each participant.  All
information collected in the survey is kept strictly
confidential.  Privacy is protected by public laws.
Uses of the Data
Information from NHANES is made available
through an extensive series of publications and
articles in scientific and technical journals.  For
data users and researchers throughout the world,
survey data are available on easy-to-use CD-
ROMS and personal computer diskettes.  In the
future, data will be widely distributed on the
World Wide Web.
Research organizations, universities, health care
providers, and educators will benefit from
survey information.  Primary data users are the
U.S. Public Health Service agencies that col-
laborated in the design and development of the
survey. The National Institutes of Health, the
Food and Drug Administration, and CDC are
among the agencies that rely upon NHANES to
provide data essential for the implementation
and evaluation of program activities.  The U.S.
Department of Agriculture and NCHS cooperate
in planning and reporting dietary and nutrition
information from the survey.
NHANES’ partnership with the U.S. Environ-
mental Protection Agency allows continued
study of the many important environmental
influences on our health.
• Oral health
• Osteoporosis
• Physical fitness and physical functioning
• Reproductive history and sexual behavior
• Respiratory disease (asthma, chronic bron-
chitis, emphysema)
































Mobile Examination Center (MEC) Diagram
Introduction

The National Health and Nutrition Examination 
Survey (NHANES) is a program of studies 
designed to assess the health and nutritional 
status of adults and children in the United 
States. The survey is unique in that it combines 
interviews and physical examinations. 
NHANES is a major program of the National 
Center for Health Statistics (NCHS). NCHS is 
part of the Centers for Disease Control and 
Prevention (CDC), U.S. Public Health Service, 
and has the responsibility for producing vital 
and health statistics for the Nation. 
The NHANES program began in the early 
1960’s and has been conducted as a series of 
surveys focusing on different population groups 
or health topics. In 1999, the survey became a 
continuous program that will have a changing 
focus on a variety of health and nutrition mea­
surements to meet emerging needs.  The survey 
examines a nationally representative sample of 
about 5,000 persons each year.  These persons 
are located in counties across the country, 15 of 
which are visited each year. 
The NHANES detailed interview includes 
demographic, socioeconomic, dietary, and 
health-related questions. The examination 
component consists of medical and dental 
examinations, physiological measurements, and 
laboratory tests administered by highly trained 
medical personnel. 
Findings from this survey will be used to deter­
mine the prevalence of major diseases and risk 
factors for diseases. Information will be used 
to assess nutritional status and its association 
with health promotion and disease prevention. 
NHANES findings are also the basis for na­
tional standards for such measurements as 
height, weight, and blood pressure. Data from 
this survey will be used in epidemiological 
studies and health sciences research, which 
help develop sound public health policy, 
direct and design health programs and 
services, and expand the health knowledge 
for the Nation. 
Survey Content 
As in past health examination surveys, data 
will be collected on the prevalence of 
chronic conditions in the population. Esti­
mates for previously undiagnosed condi­
tions, as well as those known to and reported 
by survey respondents, are produced through 
the survey.  Such information is a particular 
strength of the NHANES program. 
Risk factors, those aspects of a person’s 
lifestyle, constitution, heredity, or environ­
ment that may increase the chances of devel­
oping a certain disease or condition, will be 
examined. Smoking, alcohol consumption, 
sexual practices, drug use, physical fitness 
and activity, weight, and dietary intake will 
be studied. Data on certain aspects of repro­
ductive health, such as use of oral contracep­
tives and breastfeeding practices, also will 
be collected. 
The diseases, medical conditions, and health 
indicators to be studied include: 
• Anemia 
• Cardiovascular disease 
• Diabetes and lower extremity disease 
• Environmental exposures 
• Equilibrium 
• Hearing loss 
• Infectious diseases and immunization 
• Kidney disease 




The National Health and Nutrition Examination
Survey (NHANES) is a program of studies
designed to assess the health and nutritional
status of adults and children in the United
States.  The survey is unique in that it combines
interviews and physical examinations.
NHANES is a major program of the National
Center for Health Statistics (NCHS).  NCHS is
part of the Centers for Disease Control and
Prevention (CDC), U.S. Public Health Service,
and has the responsibility for producing vital
and health statistics for the Nation.
The NHANES program began in the early
1960’s and has been conducted as a series of
surveys focusing on different population groups
or health topics.  In 1999, the survey became a
continuous program that will have a changing
focus on a variety of health and nutrition mea-
surements to meet emerging needs.  The survey
examines a nationally representative sample of
about 5,000 persons each year.  These persons
are located in counties across the country, 15 of
which are visited each year.
The NHANES detailed interview includes
demographic, socioeconomic, dietary, and
health-related questions.  The examination
component consists of medical and dental
examinations, physiological measurements, and
laboratory tests administered by highly trained
medical personnel.
Findings from this survey will be used to deter-
mine the prevalence of major diseases and risk
factors for diseases.  Information will be used
to assess nutritional status and its association
with health promotion and disease prevention.
NHANES findings are also the basis for na-
tional standards for such measurements as
height, weight, and blood pressure.  Data from
this survey will be used in epidemiological
studies and health sciences research, which
help develop sound public health policy,
direct and design health programs and
services, and expand the health knowledge
for the Nation.
Survey Content
As in past health examination surveys, data
will be collected on the prevalence of
chronic conditions in the population.  Esti-
mates for previously undiagnosed condi-
tions, as well as those known to and reported
by survey respondents, are produced through
the survey.  Such information is a particular
strength of the NHANES program.
Risk factors, those aspects of a person’s
lifestyle, constitution, heredity, or environ-
ment that may increase the chances of devel-
oping a certain disease or condition, will be
examined.  Smoking, alcohol consumption,
sexual practices, drug use, physical fitness
and activity, weight, and dietary intake will
be studied.  Data on certain aspects of repro-
ductive health, such as use of oral contracep-
tives and breastfeeding practices, also will
be collected.
The diseases, medical conditions, and health
indicators to be studied include:
• Anemia
• Cardiovascular  disease




• Infectious diseases and immunization
• Kidney disease
• Mental health and cognitive functioning
• Nutrition
• Obesity
Uses of the Data
Information from NHANES is made available
through an extensive series of publications and
articles in scientific and technical journals.  For
data users and researchers throughout the world,
survey data are available on easy-to-use CD-
ROMS and personal computer diskettes.  In the
future, data will be widely distributed on the
World Wide Web.
Research organizations, universities, health care
providers, and educators will benefit from
survey information.  Primary data users are the
U.S. Public Health Service agencies that col-
laborated in the design and development of the
survey. The National Institutes of Health, the
Food and Drug Administration, and CDC are
among the agencies that rely upon NHANES to
provide data essential for the implementation
and evaluation of program activities.  The U.S.
Department of Agriculture and NCHS cooperate
in planning and reporting dietary and nutrition
information from the survey.
NHANES’ partnership with the U.S. Environ-
mental Protection Agency allows continued
study of the many important environmental
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• Oral health 
• Osteoporosis 
• Physical fitness and physical functioning 
• Reproductive history and sexual behavior 
• Respiratory disease (asthma, chronic bron­
chitis, emphysema) 
• Sexually transmitted diseases 
• Skin diseases 
• Vision 
The sample for the survey is selected to represent 
the U.S. population of all ages. Special emphasis 
in the current NHANES will be on adolescent 
health and the health of older Americans.  To 
produce reliable statistics for these groups, ado­
lescents 15–19 and persons 60 and older are over-
sampled for the survey. African Americans and 
Mexican Americans are also over-sampled to 
enable accurate estimates for these groups. 
Several important areas in adolescent health, 
including nutrition and fitness and other aspects 
of growth and development, will be addressed. 
Since the United States has experienced dramatic 
growth in the number of older people during this 
century, the aging population has major implica­
tions for health care needs, public policy, and 
research priorities. NCHS is working with public 
health agencies to increase the knowledge of the 
health status of older Americans.  NHANES has a 
primary role in this endeavor. 
In the examination, all participants visit the physi­
cian who takes their pulse or blood pressure. Di­
etary interviews and body measurements are 
included for everyone.  All but the very young have 
a blood sample taken and see the dentist. Depend­
ing upon the age of the participant, the rest of the 
examination includes tests and procedures to assess 
the various aspects of health listed above.  Usually, 
the older the individual, the more extensive the 
examination. Some persons who are unable to 
come to the examination center may be given a less 
extensive examination in their homes. 
Survey Operations 
Health interviews are conducted in respondents’ 
homes. Examinations are performed in spe­
cially-designed and equipped mobile examina­
tion centers, which travel to survey locations 
throughout the country. The survey team con­
sists of a physician, dentist, medical and health 
technicians, dietary and health interviewers.  A 
large staff of trained bilingual interviewers 
conducts the household interviews. 
An advanced computer system using high-end 
servers, desktop PCs, and wide-area networking 
collects and processes all of the NHANES data, 
nearly eliminating the need for paper forms and 
manual coding operations.  This system allows 
interviewers to use notebook computers with 
electronic pens.  The staff at the mobile exam 
center can automatically transmit data into data 
bases through such devices as digital scales and 
stadiometers.  Touch-sensitive computer screens 
let respondents enter their own responses to 
certain sensitive questions in complete privacy. 
Survey information is available to NCHS staff 
within 24 hours of collection, which will en­
hance the capability of collecting quality data 
and will increase the speed with which results 
are released to the public. 
In each location, local health and government 
officials are notified of the upcoming survey. 
Households in the survey receive a letter from 
the NCHS Director to introduce the survey. 
Local media may feature stories about the 
survey. 
NHANES is designed to facilitate and encourage 
participation. Transportation is provided to and 
from the examination center and participants 
receive compensation.  A report of medical and 
dental findings is given to each participant.  All 
information collected in the survey is kept strictly 
confidential. Privacy is protected by public laws. 
Introduction
The National Health and Nutrition Examination
Survey (NHANES) is a program of studies
designed to assess the health and nutritional
status of adults and children in the United
States.  The survey is unique in that it combines
interviews and physical examinations.
NHANES is a major program of the National
Center for Health Statistics (NCHS).  NCHS is
part of the Centers for Disease Control and
Prevention (CDC), U.S. Public Health Service,
and has the responsibility for producing vital
and health statistics for the Nation.
The NHANES program began in the early
1960’s and has been conducted as a series of
surveys focusing on different population groups
or health topics.  In 1999, the survey became a
continuous program that will have a changing
focus on a variety of health and nutrition mea-
surements to meet emerging needs.  The survey
examines a nationally representative sample of
about 5,000 persons each year.  These persons
are located in counties across the country, 15 of
which are visited each year.
The NHANES detailed interview includes
demographic, socioeconomic, dietary, and
health-related questions.  The examination
component consists of medical and dental
examinations, physiological measurements, and
laboratory tests administered by highly trained
medical personnel.
Findings from this survey will be used to deter-
mine the prevalence of major diseases and risk
factors for diseases.  Information will be used
to assess nutritional status and its association
with health promotion and disease prevention.
NHANES findings are also the basis for na-
tional standards for such measurements as
height, weight, and blood pressure.  Data from
this survey will be used in epidemiological
studies and health sciences research, which
help develop sound public health policy,
direct and design health programs and
services, and expand the health knowledge
for the Nation.
Survey Content
As in past health examination surveys, data
will be collected on the prevalence of
chronic conditions in the population.  Esti-
mates for previously undiagnosed condi-
tions, as well as those known to and reported
by survey respondents, are produced through
the survey.  Such information is a particular
strength of the NHANES program.
Risk factors, those aspects of a person’s
lifestyle, constitution, heredity, or environ-
ment that may increase the chances of devel-
oping a certain disease or condition, will be
examined.  Smoking, alcohol consumption,
sexual practices, drug use, physical fitness
and activity, weight, and dietary intake will
be studied.  Data on certain aspects of repro-
ductive health, such as use of oral contracep-
tives and breastfeeding practices, also will
be collected.
The diseases, medical conditions, and health
indicators to be studied include:
• Anemia
• Cardiovascular  disease




• Infectious diseases and immunization
• Kidney disease
• Mental health and cognitive functioning
• Nutrition
• Obesity
The sample for the survey is selected to represent
the U.S. population of all ages.  Special emphasis
in the current NHANES will be on adolescent
health and the health of older Americans.  To
produce reliable statistics for these groups, ado-
lescents 15–19 and persons 60 and older are over-
sampled for the survey. African Americans and
Mexican Americans are also over-sampled to
enable accurate estimates for these groups.
Several important areas in adolescent health,
including nutrition and fitness and other aspects
of growth and development, will be addressed.
Since the United States has experienced dramatic
growth in the number of older people during this
century, the aging population has major implica-
tions for health care needs, public policy, and
research priorities.  NCHS is working with public
health agencies to increase the knowledge of the
health status of older Americans.  NHANES has a
primary role in this endeavor.
In the examination, all participants visit the physi-
cian who takes their pulse or blood pressure.  Di-
etary interviews and body measurements are
included for everyone.  All but the very young have
a blood sample taken and see the dentist.  Depend-
ing upon the age of the participant, the rest of the
examination includes tests and procedures to assess
the various aspects of health listed above.  Usually,
the older the individual, the more extensive the
examination.  Some persons who are unable to
come to the examination center may be given a less
extensive examination in their homes.
Survey Operations
Health interviews are conducted in respondents’
homes.  Examinations are performed in spe-
cially-designed and equipped mobile examina-
tion centers, which travel to survey locations
throughout the country. The survey team con-
sists of a physician, dentist, medical and health
technicians, dietary and health interviewers.  A
large staff of trained bilingual interviewers
conducts the household interviews.
An advanced computer system using high-end
servers, desktop PCs, and wide-area networking
collects and processes all of the NHANES data,
nearly eliminating the need for paper forms and
manual coding operations.  This system allows
interviewers to use notebook computers with
electronic pens.  The staff at the mobile exam
center can automatically transmit data into data
bases through such devices as digital scales and
stadiometers.  Touch-sensitive computer screens
let respondents enter their own responses to
certain sensitive questions in complete privacy.
Survey information is available to NCHS staff
within 24 hours of collection, which will en-
hance the capability of collecting quality data
and will increase the speed with which results
are released to the public.
In each location, local health and government
officials are notified of the upcoming survey.
Households in the survey receive a letter from
the NCHS Director to introduce the survey.
Local media may feature stories about the
survey.
NHANES is designed to facilitate and encourage
participation.  Transportation is provided to and
from the examination center and participants
receive compensation.  A report of medical and
dental findings is given to each participant.  All
information collected in the survey is kept strictly
confidential.  Privacy is protected by public laws.
• Oral health
• Osteoporosis
• Physical fitness and physical functioning
• Reproductive history and sexual behavior
• Respiratory disease (asthma, chronic bron-
chitis, emphysema)
• Sexually transmitted diseases
• Skin diseases
• Vision
Uses of the Data 
Information from NHANES is made available 
through an extensive series of publications and 
articles in scientific and technical journals. For 
data users and researchers throughout the world, 
survey data are available on easy-to-use CD­
ROMS and personal computer diskettes. In the 
future, data will be widely distributed on the 
World Wide Web. 
Research organizations, universities, health care 
providers, and educators will benefit from 
survey information. Primary data users are the 
U.S. Public Health Service agencies that col­
laborated in the design and development of the 
survey. The National Institutes of Health, the 
Food and Drug Administration, and CDC are 
among the agencies that rely upon NHANES to 
provide data essential for the implementation 
and evaluation of program activities.  The U.S. 
Department of Agriculture and NCHS cooperate 
in planning and reporting dietary and nutrition 
information from the survey. 
NHANES’ partnership with the U.S. Environ­
mental Protection Agency allows continued 
study of the many important environmental 
influences on our health. 





























For more information about the National Center for Health Statistics contact:
Data Dissemination Branch
National Center for Health Statistics
Room 1064, Metro III Bldg.
6525 Belcrest Road
Hyattsville, Maryland 20782-2003
Telephone: (301) 458-INFO (4636)
E-mail: nchsquery@cdc.gov
Internet: www.cdc.gov/nchs
For more information about the National Health and Nutrition Examination Survey
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Overview
NHANES’ record of important accomplishments is 
made possible by the thousands of Americans who 
have participated. 
•	 Past surveys have provided data to create the 
growth charts used nationally by pediatricians 
to evaluate children’s growth.  The charts have 
been adapted and adopted worldwide as a 
reference standard—and have recently been 
updated using the latest NHANES figures. 
•	 Blood lead data were instrumental in develop­
ing policy to eliminate lead from gasoline and 
solder in food and soft drink cans. Recent 
survey data indicate the policy has been even 
more effective than originally envisioned, 
with a decline in elevated blood lead levels of 
more than 70% since the 1970’s. 
•	 Overweight prevalence figures have led to the 
proliferation of programs emphasizing diet 
and exercise, stimulated additional research, 
and provided a means to track trends in obesity.
 •	 Data have continued to indicate that undiag­
nosed diabetes is a significant problem in the 
United States.  Efforts by Government and 
private agencies to increase public awareness, 
especially among minority populations, have 
been intensified. 
These are just a few examples of what survey 
findings have meant.  The current program 
promises continuing contributions and some new 
initiatives.
 •	 Information collected in this survey will help 
the Food and Drug Administration decide if 
there is a need to change vitamin and mineral 
fortification regulations for the Nation’s food 
supply.
 •	 The national programs to reduce hypertension 
and cholesterol levels continue to depend on 
NHANES data to steer education and preven­
tion programs toward those at risk and to 
measure success in curtailing risk factors 
associated with heart disease, the Nation’s 
number one cause of death.
 •	 New measures of physical fitness will 
further our understanding of its role in 
health and enhance the analysis of 
relationships between exercise and obesity 
and disease. 
Because NHANES is now an ongoing pro­
gram, the information collected will contrib­
ute to annual estimates in some topic areas 
included in the survey.  For small population 
groups and less prevalent conditions and 
diseases, data must be accumulated over 
several years to provide adequate estimates. 
The new continuous design also allows 
increased flexibility in survey content. 
Results of NHANES will benefit people in 
the United States in important ways. Facts 
about the distribution of health problems and 
risk factors in the population give researchers 
important clues to the causes of disease. 
Information collected from the current survey 
will be compared with information collected 
in previous surveys.  This will allow health 
planners to detect the extent various health 
problems and risk factors have changed in the 
U.S. population over time. By identifying the 
health care needs of the population, govern­
ment agencies and private sector organiza­
tions can establish policies and plan research, 
education, and health promotion programs 
that will help improve present health status 
and prevent future health problems. 
NHANES’ record of important accomplishments is
made possible by the thousands of Americans who
have participated.
• Past surveys have provided data to create the
growth charts used nationally by pediatricians
to evaluate children’s growth.  The charts have
been adapted and adopted worldwide as a
reference standard—and have recently been
updated using the latest NHANES figures.
• Blood lead data were instrumental in develop-
ing policy to eliminate lead from gasoline and
solder in food and soft drink cans.  Recent
survey data indicate the policy has been even
more effective than originally envisioned,
with a decline in elevated blood lead levels of
more than 70% since the 1970’s.
• Overweight prevalence figures have led to the
proliferation of programs emphasizing diet
and exercise, stimulated additional research,
and provided a means to track trends in obesity.
 • Data have continued to indicate that undiag-
nosed diabetes is a significant problem in the
United States.  Efforts by Government and
private agencies to increase public awareness,
especially among minority populations, have
been intensified.
These are just a few examples of what survey
findings have meant.  The current program
promises continuing contributions and some new
initiatives.
 • Information collected in this survey will help
the Food and Drug Administration decide if
there is a need to change vitamin and mineral
fortification regulations for the Nation’s food
supply.
 • The national programs to reduce hypertension
and cholesterol levels continue to depend on
NHANES data to steer education and preven-
tion programs toward those at risk and to
measure success in curtailing risk factors
associated with heart disease, the Nation’s
number one cause of death.
 • New measures of physical fitness will
further our understanding of its role in
health and enhance the analysis of
relationships between exercise and obesity
and disease.
Because NHANES is now an ongoing pro-
gram, the information collected will contrib-
ute to annual estimates in some topic areas
included in the survey.  For small population
groups and less prevalent conditions and
diseases, data must be accumulated over
several years to provide adequate estimates.
The new continuous design also allows
increased flexibility in survey content.
Results of NHANES will benefit people in
the United States in important ways.  Facts
about the distribution of health problems and
risk factors in the population give researchers
important clues to the causes of disease.
Information collected from the current survey
will be compared with information collected
in previous surveys.  This will allow health
planners to detect the extent various health
problems and risk factors have changed in the
U.S. population over time.  By identifying the
health care needs of the population, govern-
ment agencies and private sector organiza-
tions can establish policies and plan research,
education, and health promotion programs
that will help improve present health status
and prevent future health problems.
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Telephone: (301) 458-INFO (4636) 
E-mail: nchsquery@cdc.gov 
Internet: www.cdc.gov/nchs 
For more information about the National Health and Nutrition Examination Survey 
you may visit the NHANES web site at: www.cdc.gov/nhanes 
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